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Abstract
Obesity-induced hyperlipidemia is one of the main factors for female infertility.
Hyperlipidemia, specifically with high levels of palmitic acid (PA) and oleic acid (OA),
interferes with preimplantation development. Autophagy is essential in early embryo
development but, it is unknown whether hyperlipidemia affects autophagic mechanisms in
preimplantation embryos. It was hypothesized that PA will alter autophagy in
preimplantation mouse embryos and that the subsequent effects will be reversed by OA. PA
impaired blastocyst development by arresting embryos at the 8-cell stage. PA also elevated
early embryo autophagy by increasing autophagosome formation, decreasing maturation, and
disrupting degradation. Co-treatment with OA showed developmental delay at the early
preimplantation stages but restored blastocyst formation. OA treatment also counteracted
PA-induced effects on autophagy. Overall, PA altered autophagy at various levels, was
reversed by the addition of OA. Ultimately, we aim to assist obese patients by offsetting the
negative

effects

of

hyperlipidemia

on

preimplantation

embryo

development.
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Summary for Lay Audience
Obesity is a one of the main factors for infertility in Canadian females. Levels of fatty acids
like palmitic acid (PA) and oleic acid (OA) are elevated in obese individuals. Previously, we
reported that PA disrupts mouse embryonic development and addition of OA reversed those
effects. Autophagy is another important mechanism in early embryo development in which
useless contents are packaged into autophagosomes for degradation to be reused in other
cellular functions. Despite the importance of autophagy in embryonic development, it is
undefined whether autophagy is affected by elevated levels of fatty acids in preimplantation
embryos. To determine the effects of PA and OA, mouse embryos were treated with PA and
OA, alone and in combination for up to 48 hours. PA prevented embryonic development by
arresting development at the 8-cell stage. PA also resulted in elevated levels of autophagy by
disrupting autophagosome formation and lowering autophagosome maturation and
degradation. OA addition to PA treatment resulted in developmental delay at the early
embryonic stages but restored normal levels of development at the later stages. Additionally,
PA and OA co-treatment reversed PA-effects on autophagic mechanisms of preimplantation
mouse embryos. Overall, PA impaired development and elevated autophagy and the addition
of OA counteracted those effects. With these findings, we expect to help obese individuals
with their fertility problems by offsetting the negative effects of obesity on preimplantation
embryo development.
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Chapter 1

1

Introduction

1.1 Preimplantation Embryo Development
Preimplantation embryo development occurs within the reproductive tract of the mother.
Preimplantation embryo development defines the period from the fertilization of an
oocyte with a sperm to the attachment of an embryo to the uterine wall (Shi and Wu
2009). Fertilization occurs when a sperm enters the oocyte and a zygote is formed,
initiating preimplantation development (Li and Winuthayanon 2017). Preimplantation
embryo development can be separated into two parts – cleavage division(s) and
blastocyst formation (cavitation) (Shi and Wu 2009).

1.1.1

Cleavage Division

Cleavage division (cell division) begins approximately 24 to 36 hours after fertilization
(O’Farrell et al. 2004). The one-cell zygote subdivides into two-, four-, eight-, then 16cells and on at approximately 12-hour intervals from the two-cell stage to the early
blastocyst stage (O’Farrell et al. 2004). At the two-cell stage, mouse embryos undergo
zygotic genome activation (ZGA). ZGA enables the activation of embryonic genome
(mRNA transcription and protein translation) while degrading maternal oogenetic
products (Lee et al. 2014). ZGA plays an important role in activating the genomic
cascade or program that supports early preimplantation development and implantation of
an embryo (Jukam et al. 2017). At the eight-cell stage, compaction of the embryo is
triggered (Kojima et al. 2014). Compaction creates morula staged embryos, which are
defined by a morphogenetic event that results in the individual outlines of all embryonic
blastomeres (cells) disappearing, due to the formation of functioning cell to cell adherens
junctions (Kojima et al. 2014). In addition, the blastomeres begin to lose their
totipotency, which is the ability to differentiate into all developmental cell types
(Chazaud and Yamanaka 2016). Compaction thus initiates the process of developmental
cell fate determination and cell differentiation (Chazaud and Yamanaka 2016). It is a
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necessary prelude to blastocyst formation and ultimately embryo implantation. Summary
of cleavage division during preimplantation development is displayed in figure 1.

1.1.2

Blastocyst Formation

Following compaction and morula formation, blastocyst formation or cavitation is
initiated (Kojima et al. 2014). The blastocyst consists of a fluid-filled cavity, an outer cell
layer known as the trophectoderm (TE), and an inner cell core known as the inner cell
mass (ICM) (Frankenberg et al. 2016). Cavitation begins as a morula cavitate with fluid
transport into the embryo via ion channels, resulting in the formation of a nascent fluidfilled blastocyst cavity (Kojima et al. 2014). The volume of the fluid within the cavity is
controlled by the trophectoderm undergoing regulatory changes to retain or release fluid,
thereby expanding or contracting the blastocyst (Wiley 1984). The blastomeres polarized
during compaction express lineage-specific genes for TE or ICM development (Chazaud
and Yamanaka 2016). The trophectoderm mediates embryo implantation by interacting
with the uterine wall and eventually contributes directly to the placenta at implantation
and as placentation events are initiated (Frankenberg et al. 2016). The inner cell mass
consists of pluripotent cell types that represent the origin of the three primary germ layers
(Chazaud and Yamanaka 2016). The timing from cavitation to implantation takes
approximately 24 hours in the mouse (O’Farrell et al. 2004). Summary of blastocyst
formation during preimplantation development is displayed in figure 1.
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Figure 1. Summary of mammalian preimplantation embryo development and
developmental events.
Mammalian preimplantation embryo development starts after fertilization of an oocyte by
a sperm to form a zygote. The zygote undergoes cleavage divisions and compaction to
eventually form a blastocyst. Main developmental events are displayed. Time of
developmental events differ between each mammalian species. Maternal genome product
diminishes over time as preimplantation embryos progress through each cell stages;
zygotic genome product is gradually produced over time as the embryo progresses
through preimplantation stages. Cleavage division occurs throughout development, from
the 1-cell stage to the morula stage and beyond. At the 8-cell stage, compaction and cell
fate determination occurs to prepare for blastocyst formation. Cavitation occurs at the
morula stage as fluid-filled cavity is formed to create a blastocyst with trophectoderm and
pluripotent inner cell mass. Created with BioRender.com.
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1.2 Female Infertility
Infertility defines the inability of otherwise healthy human couples to achieve pregnancy
within a year of unprotected intercourse. The World Health Organization (WHO)
estimates that infertility affects 186 million individuals worldwide (World Health
Organization). The global burden of disease study in 2017 identified that infertility
prevalence rate significantly increased by 15 % from 1990 to 2017 (Sun et al. 2019). This
study discovered that countries with high socioeconomic development, for example,
Canada, had the highest increase in infertility rate in females. Roughly 16 % of Canadian
couples experience infertility and at least 40 % of the time it is due to difficulties
experienced by females (Public Health Agency of Canada). Female infertility is
influenced by many factors including age, genetics, as well as lifestyle-related factors.
Presently, the mean maternal age of first childbirth is 30 in European countries (Vander
Borght and Wyns 2018). Fertility declination correlates to maternal age and was reported
to begin as early as 25 years of age (Eijkemans et al. 2014). Eijkemans et al. (2014)
analyzed that age-related infertility exponentially increases from 4.5 % at age 25 to about
50 % at age 40, likely due to the loss of oocyte number and quality. Genetics could also
predispose women of conditions and diseases that affect fertility, for example, polycystic
ovary syndrome, that result in irregular ovulation pattern (Franks 2008). Lifestyle choices
like smoking, alcohol, and drug consumptions are evidently factors for infertility that
impairs reproductive functions (Vander Borght and Wyns 2018).

1.3 Assisted Reproductive Technologies (ART)
As the infertility rate increases, many people turn to assisted reproductive technologies
(ART) for their fertility needs. In 2010, the International Federation of Fertility Societies
reported that there are at least 4400 ART clinics worldwide (Jones Jr. et al. 2011), with
37 ART clinics across Canada in 2019 (Canadian Fertility & Andrology Society).
According to the Canadian Assisted Reproductive Technologies Register, more than
35,000 ART treatment cycles were initiated in 2019 and resulted in about 17,000 clinical
pregnancies (Canadian Assisted Reproductive Technologies Registry (CARTR) Plus).
Some of the ART interventions performed in 2019 were in vitro fertilization (IVF),
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intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), in vitro oocyte
maturation (IVM), and frozen embryo transfer, to name a few.

1.4 Obesity
As classified by the World Health Organization (WHO), individuals with a body mass
index (BMI) of 25 or more are considered overweight; and individuals with a BMI of 30
or more are considered obese. The WHO estimated that in 2016, more than half of the
adults worldwide were overweight or obese (World Health Organization). Statistics
Canada (2019) also reported that 63 % of Canadian adults were overweight or obese in
2018; 57 % of them are females within that population. Obesity is defined as a chronic
disease by the Obesity Society (Jastreboff et al. 2019) resulting from an excess
accumulation of lipid that leads to inflammation, perhaps metabolic disorder, and
certainly stress in many parts of the body. It impairs vital bodily functions by placing
stress on the cardiac system, weakening immunity, and disrupting endocrine functions
(Conway and Rene 2004). High BMI levels are associated with a higher risk of
cardiovascular disorder, according to the Framingham Heart study (Wilson et al. 2002).
Analysis of the study identified a strong connection between increased risk for heart
failure correlating with increasing BMI level, in which the risk of heart failure increases
by 5 and 7 % for each increment of BMI levels in males and females, respectively
(Kenchaiah et al. 2002). Obesity also suppresses immunity. The analysis of the National
Health and Nutrition Examination Survey III by the US Centers for Disease Control
revealed associations between BMI levels and pulmonary infection rate (Ubags et al.
2016). Specifically, high levels of serum leptin, released by the accumulation of adipose
tissue, increases risk for pulmonary infections by impairing neutrophil function (Ubags et
al. 2016). Hyperleptinemia is also associated with an increased risk of death from
pneumonia, as evident from the analysis of Influenza A pandemic in 2009 (Louie et al.
2011). These studies support the recent discovery that obesity predisposes COVID-19
patients to more severe symptoms (Sattar et al. 2020). Additionally, obesity disrupts
endocrine functioning, namely insulin resistance. Elevated levels of glucose and free fatty
acids in the circulation stimulates additional release of insulin by the pancreas to initiate
glucose uptake (Lauterbach and Wunderlich 2017). Excessive release of insulin decreases
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insulin sensitivity of the liver and peripheral muscles, eventually contributing to insulin
resistance and metabolic diseases as a result (Lauterbach and Wunderlich 2017).

1.5 Obesity on Female Reproductive Health
Studies have clearly determined that obesity negatively affects reproductive health in
both sexes, but in women, these effects include menstrual abnormalities (Seif et al. 2015),
ovarian dysfunction (Nteeba et al. 2014), diminished oocyte quality (Hou et al. 2016),
reduced endometrial sensitivity for implantation (Rhee et al. 2016), and overall
significant reduction in pregnancy rate (Broughton and Moley 2017). Overweight and
obese women have twice the likelihood of experiencing irregular menstrual cycles than
healthy individuals (Wei et al. 2009). These women experience heavier menstrual
bleeding, compared to normal and underweight women. (Mena et al. 2021). Additionally,
obesity and high body fat percentage is significantly associated with mean menstrual
cycle length of longer than 32 days compared to an average of 28 days in healthy
individuals (Lay et al. 2021). Luteinizing hormone (LH), a gonadotrophin hormone that
regulates the menstrual cycle and initiates ovulation of an oocyte, is implicated in these
obesity related effects in women. A study of obese teenagers with abnormal menstrual
cycles found a significantly higher LH pulse frequency than that of healthy-weight girls
(Yoo et al. 2006). Another study of obese adult women identified a lower amplitude of
LH secretion than normal-weighted women, although no difference in LH pulse
frequency was observed in this study (Jain et al. 2007). Along with many others, these
studies support that normal secretory pattern of gonadotrophin hormones like LH are
implicated in women with high BMI levels. Normally, leptin production from adipose
tissue stimulates the hypothalamic-pituitary-gonadal (HPG) axis that induces
gonadotrophin-releasing hormone (GnRH) expression in the brain to produce LH at the
gonads (Tsatsanis et al. 2015). Under obese conditions, high leptin levels from excess
adipose tissue continuously stimulate the HPG axis and eventually lead to leptin
resistance which disrupts regulation of GnRH and LH levels (Tsatsanis et al. 2015).
Changes in gonadotrophin hormones from elevated body fat disrupt normal menstrual
cycle, which contributes to reduced reproductive competency of obese women.
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A meta-analysis identified that overweight and obese women (BMI > 25 kg/m2)
experience significantly higher odds for miscarriage than women with normal BMI,
regardless of the method of conception (Metwally et al. 2008). Elevated body fat levels
disrupt ovarian functions by inducing inflammation and macrophage infiltration. Mice
placed under a prolonged high fat diet displayed increased ovarian tissue inflammation
and lowered pregnancy rate (Skaznik-Wikiel et al. 2016). In women undergoing IVF
treatments, monocyte chemotactic protein-1 (MCP-1) levels were positively correlated
with rising BMI in serum and follicular fluid (Buyuk et al. 2017). MCP-1 is an important
factor for the recruitment and infiltration of immune cells. Although MCP-1 is normally
elevated during the menstrual cycle to support ovulation (Bornstein et al. 2004), obesity
appears to increase MCP-1 expression at the ovaries aberrantly. It results in the
infiltration of additional monocytes and contributes to inflammation of the ovaries, thus
impacting normal ovarian functions (Buyuk et al. 2017). Studies have suggested that
elevated leptin levels in obese women may lower endometrial receptivity for embryo
implantation due to the regulatory role of leptin in endometrial cells (Gonzalez and
Leavis 2001; Broughton and Moley 2017). However, the role of elevated leptin in
pregnancy is controversial as studies are inconsistent with regards to reporting obesityinduced hyperleptinemia as a factor for miscarriage (Brewer and Balen 2010). The
declination in oocyte developmental competency is the key way in which hyperlipidemia
reduces chances of a successful embryo implantation.
Obesity also disrupts endocrine functioning of reproductive hormones that are vital for a
successful pregnancy. Hyperandrogenism, defined as the elevated levels of ovarian
androgens, such as testosterone, is common in obese women (Poddar et al. 2017).
Corbould (2007) identified that the chronic exposure to testosterone impairs glucose
metabolism in subcutaneous adipose tissue. The phosphorylation of protein kinase C zeta,
downstream of the insulin receptor in adipose tissue, was inhibited, thus resulting in
insulin resistance and alters glucose uptake in adipose tissue (Corbould 2007).
Hyperandrogenism contributes to insulin resistance and adipose accumulation at the
ovaries, which exacerbates the effects of obesity on women’s reproductive health (Zeng
et al. 2019). In addition to the change in testosterone level, estrogen levels are also
affected by BMI. The previously mentioned study by Shah et al. (2011) observed a
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significantly lower estradiol level in women with a high BMI than women with a normal
BMI. The lowered estradiol level supports the occurrence of reduced oocyte fertilization
in the high BMI group (Shah et al. 2011), as proper estrogen levels are essential to
support healthy oocyte maturation.
Lastly, it is evident that women with higher BMI levels have higher levels of
triglycerides, insulin, and lactate present in the follicular fluid (Robker et al. 2009).
Investigations of women undergoing IVF treatments, with different follicular free fatty
acid levels have discovered an important correlation between higher follicular free fatty
acid levels and increased poor-quality oocytes (Jungheim et al. 2011). Women displaying
higher follicular free fatty acids also have fewer normally fertilized oocytes compared to
women with a normal BMI and they experience a 50 % lower chance of achieving a
clinical pregnancy after IVF treatments (Shah et al. 2011).
Overall, obesity is detrimental to not only maternal reproductive health, but more
specifically to oocyte and early embryonic developmental competency. Most obese
women of reproductive age experience difficulties with conception (Vahratian 2008),
even with the help of ART. Women with high BMI levels have much lower ART success
which in parts results from reduced oocyte developmental competence, in vitro
fertilization success, and overall lower live birth rates (Shah et al. 2011). However, the
underlying mechanisms that lead to these effects of obesity on fertility largely remain to
be discovered.

1.6 Lipid Metabolism
Lipid metabolism covers the biochemistry of lipid biosynthesis and degradation.
Nutrients like carbohydrates and lipids from dietary sources are processed by gut
microbiota to be taken up by intestinal cells (Schoeler and Caesar 2019). These nutrients
are then transported from the intestine to the liver and other peripheral organs like
adipose and muscle tissues for metabolism. Under nutrient-rich environments,
carbohydrates are processed through glycolysis into acetyl-CoA. Then, after a series of
reactions through the lipogenic pathway, fatty acids are generated (Ameer et al. 2014). In
the liver, these fatty acids act as an energy source and provide structural components for
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cellular membrane; while in the adipose tissues, fatty acids are synthesized through
lipogenesis and stored as lipid droplets for long-term energy storage (Nguyen et al.
2008). Lipids from dietary sources are taken up by intestinal cells and converted to
triacylglycerol (TAG) to be transported in the circulation inside a chylomicron
(Mansbach and Siddiqi 2010). The transport of TAG in a chylomicron to the liver and
peripheral lipid metabolic sites enables lipoprotein lipase in capillaries to hydrolyze TAG
for subsequent oxidation or storage of the energy source (Karpe et al. 2011). Under
starvation, the breakdown of TAG and lipoprotein storage in the liver occurs to provide
energy for organ system functioning. Fatty acid oxidation, the process in which acetylCoA is produced from fatty acids through the β-oxidation, occurs in support of energy
expenditure (Nguyen et al. 2008). Ketogenesis also occurs to oxidize fatty acids in the
conversion of acetyl-CoA into ketone bodies as a quick strategy against energy starvation
(Nguyen et al. 2008). Lastly, hepatic lipoproteins are transported to the hepatocyte
membranes to release TAG into the circulation. The circulatory transport of TAG to other
organs like muscle tissues results in the breakdown of TAG through lipolysis to provide
energy for muscle activity (Nguyen et al. 2008).

1.7 Lipid Metabolism in Female Reproduction
As described, lipid metabolism is an important source of energy for cell physiology. It
provides energy for many organ systems including the reproductive system. The
developmental competency of oocytes is highly dependent on cumulus cells and their
ability to utilize glucose or fatty acids through glycolysis and β-oxidation, respectively,
as an energy source (Warzych and Lipinska 2020, Richani et al. 2021). Cumulus cells
contribute largely, via gap junctions, to oocyte development by supplying most of the
ATP and substrates like pyruvate that are required for energy expenditure (Richani et al.
2021). Oocytes can also generate ATP although mitochondria are pre-mature. Richani et
al. (2019) showed that the production of ATP in denuded mouse oocytes occur via the
adenosine salvage pathway, though the ATP production was at a much lower level. The
utilization of fatty acids in oocytes and cumulus cells is also an important source of
energy as the inhibition of β-oxidation of mouse cumulus-oocyte complex inhibits oocyte
maturation and reduces blastocyst development (Dunning et al. 2010). Fatty acids are
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stored as TAG in lipid droplets in the oocytes until oxidation for energy consumption
(Bradley and Swann 2019). The amount and composition of lipid droplets in the oocyte
changes throughout follicular development and differs between species (Bradley and
Swann 2019). Clearly, fatty acid metabolism is required to provide sufficient energy
substrates like NADH, FADH2, GTP, and ATP to support oocyte maturation. The energy
produced from lipid metabolism also supports development of an early embryo,
especially during the earliest cleavage events. For example, oxidation of stored TAG
liberates fatty acids and phospholipids that support the increase of cell membrane surface
area throughout preimplantation development (Bradley and Swann 2019).

1.8 Non-esterified Fatty Acids (NEFA)
Obesity results from the accumulation of adipose tissue, which is reflected by the level of
non-esterified fatty acids (NEFA) in the serum (Boden 2011). NEFAs are fatty acids
released into the circulation from adipose tissues, as a result of lipolysis of TAG in the
adipocytes (Karpe et al. 2011). The release of NEFA allows transport of fatty acids to
other organs to produce energy. Another major source of NEFA in the circulation is
dietary lipid intake. These lipid droplets are transported to the liver as TAG in
chylomicrons and must be hydrolyzed into NEFA by lipoprotein lipase before taken up
for long-term storage (Karpe et al. 2011). Although early literature suggested that an
increase in adipose tissue mass leads to elevated levels of NEFA in the circulation (Opie
and Walfish 1963), many studies have shown the opposite. For example, McQuaid et al.
(2011) reported that obese individuals have a systemic NEFA concentration no different
from lean individuals. The rate of lipoprotein lipase activity in obese individuals was in
fact lowered, which actually reduces the levels of NEFA released from the adipose tissue
(McQuaid et al. 2011). Karpe et al. (2011) also completed a systematic review of the
literature prior to 2009 and found that plasma NEFA concentration is unrelated to body
fat mass. However, while the reliability of serum NEFA levels as an estimation for
obesity or body fat accumulation is questioned, the composition and relative ratios of
varying NEFAs in the circulation of obese individuals likely reflect the degree of
negative effects related to the obese environment.
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The follicular NEFA composition and ratios varies across individuals. Fatty acids in the
circulation are transported to the ovaries and follicular fluid. Then the fatty acids are
taken up by cumulus cells and transported into oocytes through fatty acid binding
proteins in the cumulus cell-oocyte gap junctions (Aardema et al. 2019). Multiple studies
reporting analyses of oocyte follicular fluids have found varying composition of fatty
acids based on different diet composition and variation in tissue metabolic rate
differences (Bradley and Swann 2019). However, analysis of human follicular fluids
identified that approximately 45 % of total NEFAs are palmitic acid (PA) and oleic acid
(OA) (Valckx et al. 2014). These free fatty acids are at an even higher circulatory
concentrations in people who are overweight and obese compared to normal BMI
individuals (Valckx et al. 2014).
NEFAs can be categorized into two main categories – saturated fatty acids and
unsaturated fatty acids. Saturated fatty acids are fatty acids with no double-bonds
between their carbon chain, whereas unsaturated fatty acids are fatty acids with at least
one double-bond between their carbon chain. PA and OA are the most abundant saturated
and non-saturated NEFAs, respectively, in the circulation, estimating at 23 % and 31 %
of total NEFA, respectively of normal-weight subjects (Valckx et al. 2014).

1.9 Palmitic Acid (PA)
1.9.1

Structure and Source of PA

Palmitic acid (16:0; PA) is a 16-carbon saturated fatty acid. It can be synthesized in the
body de novo through lipogenesis from other macromolecules and it is also be ingested in
the diet (Carta et al. 2017). PA is abundant in palm oil, meat, and dairy products. Under
nutrient-rich conditions, PA concentration is tightly controlled by desaturation to other
unsaturated fatty acids like palmitoleate (16:1) for long-term lipid storage (Strable and
Ntambi 2010). However, with an imbalance of PA homeostasis, implications in
metabolism occurs leading to metabolic syndromes like insulin resistance and even
cancer (Carta et al. 2017).
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1.9.2

The Effect of PA on Embryo Development

The effects of PA on bovine and mouse preimplantation embryo development are
previously described in the literature. PA is one of the major fatty acids making up
approximately 25 % of total NEFA present in bovine follicular fluid (Leroy et al. 2005).
A study by Aardema et al. (2019) reported a lowered uptake of PA compared to control
in bovine oocytes. Lipid droplet sizes and numbers were also significantly smaller in PAtreated oocytes (Aardema et al. 2019). Additionally, oocyte maturation after fertilization
was greatly reduced in a dose-dependent manner after PA-exposure (Aardema et al.
2011). Leroy et al. (2005) reported that in vitro maturation bovine oocytes in medium
containing PA results in a significantly lower fertilization rate compared to control.
Oocyte maturation was also disrupted by the presence of PA in the culture media, as a
significantly higher percentage of oocytes experienced delayed progression through
meiosis (Leroy et al. 2005). Furthermore, the effects of PA on bovine embryos
investigated by Van Hoeck et al. (2011) found that high PA culture medium significantly
lowered blastocyst development as well as increased apoptotic cell ratio. We have
reported similar effects in mouse preimplantation development recently. After in vitro
incubation of mouse embryos at the 2-cell stage in PA supplemented culture medium,
Yousif et al. (2020) demonstrated impairments of mouse blastocyst development in a
dose-dependent manner. Furthermore, it was identified that PA upregulated ER stress
markers at the transcript level, providing evidence that exposure to elevated PA may
induce cell stress that impairs mouse preimplantation development (Yousif et al. 2020). A
similar study by Jungheim et al. (2011) reported a reduced cell count in mouse
blastocysts after in vitro incubation with PA for 30 hrs. The researchers also identified a
significantly upregulated Insulin-like growth factor type-1 receptor (IGF-1R) and
glutamic-pyruvate transaminase 2 (GPT2) protein expression, which may contribute to
abnormal insulin signaling in these embryos. When the PA-treated blastocysts were
transferred into pseudo-pregnant female mice and grown to birth, those embryos
developed into significantly smaller fetuses than the fetuses from control embryos
(Jungheim et al. 2011). Although fetuses from PA-treated embryos were possibly growthrestricted, a catch-up growth pattern was observed, and those fetuses eventually grew
heavier than control fetuses on day 50 (Jungheim et al. 2011). These findings imply that
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PA exposure alone can lead to metabolic changes in the offspring, which shows
relevancy to insulin resistance in obese individuals.

1.9.3

The Effects of PA on Other Cell Types

The effects of PA treatment on somatic cell types are extensively investigated. A study
by Staiger et al. (2004) demonstrated the effects of PA treatment on cardiac cells by the
expression of the inflammatory marker, interleukin-6 (IL-6). The researchers identified
that PA induced significant increases in IL-6 mRNA and protein expression in coronary
artery endothelial cells and coronary artery smooth muscle cells in vitro (Staiger et al.
2004). Additionally, a significant positive correlation between PA and IL-6 concentration
in the circulation of non-diabetic individuals was observed (Staiger et al. 2004). These
findings revealed that a high level of PA in the circulation contributes to cardiovascular
inflammatory responses and potentially heightens the risk of cardiovascular diseases, as
seen in diets with high saturated fats (Sacks et al. 2017). A PA-rich diet negatively affects
pulmonary cell types as well. Chu et al. (2019) identified that a high PA diet increases the
risk of lung fibrosis and mortality in mice. It was revealed that in mouse lung epithelial
cells, PA treatment induces protein expression of ER stress pathway constituents and
leads to apoptosis, which may explain the fibrotic phenotype observed in vivo (Chu et al.
2019). As lipid metabolism takes place in the liver, there is no doubt that PA levels can
impose a negative effect on hepatic cells. Joshi-Barve et al. (2007) exposed HepG2 cells
to excess PA to induce PA accumulation in the hepatocytes. The accumulation of PA in
the hepatocytes induced significant increases in mRNA and protein expression of the
inflammatory marker interleukin-8 (IL-8) (Joshi-Barve et al. 2007). It was suggested that
enhanced IL-8 expression in the hepatocyte contributes to inflammation, which
potentially plays a role in liver steatosis and liver diseases in obese individuals. Once
again, it was demonstrated that PA induces inflammatory responses that contribute to
severe pathophysiological conditions in multiple systems of the body.
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1.10 Oleic Acid (OA)
1.10.1

Structure and Source of OA

Oleic acid (18:1; OA) is an 18-carbon monounsaturated fatty acid. It is a major
component of olive oil, make up to 83 % of olive oil’s total composition (Marcelino et al.
2019). Like PA, OA can be synthesized de novo through lipogenesis and thus dietary
intake is not deemed a necessity. However, the recent increase in popularity of the
Mediterranean diet places an emphasis on the beneficial effects of ingesting unsaturated
fatty acids like OA. Recent research efforts have identified the Mediterranean diet, which
consists of mostly fruits and vegetables, as well as the consumption of extra virgin olive
oil as a main source of fats, reduces the risk of chronic diseases and mortality (Tosti et al.
2018). With promising results from multiple randomized clinical trials, the American
Heart Association recommends lower intake of saturated fats and replacing fat intake
with unsaturated fats to lower the risk of cardiovascular events (Sacks et al. 2017).

1.10.2

The Effects of OA on Embryo Development

Among the many NEFAs, OA is another major type of fatty acids found in the
reproductive system, including the follicular fluid. It is estimated to make up
approximately 30 % of total NEFA in bovine follicular fluid (Leroy et al. 2005). A study
by Aardema et al. (2011) investigated the effects of OA treatment on bovine oocyte
developmental competency and lipid metabolism. OA had no negative effect on oocyte
maturation and in vitro exposure to OA simply increased lipid droplet sizes and numbers
in the oocytes (Aardema et al. 2011). It was also indicated that OA was primarily
metabolized into its subsequent products from β-oxidation or processed as TAG for longterm storage (Aardema et al. 2011). Similarly, Leroy et al. (2005) reported that in vitro
incubation of bovine oocytes with OA had no significant effects on oocyte maturation as
well as blastocyst development after fertilization. Another study of bovine embryos with
exogenous medium supplementation with OA indicated a significant increase in cleavage
rate at the 2-cell stage as well as a significant increase in blastocyst development
(Karaşahin and Arikan 2015). Generally, it is concluded that OA has no discernable
negative impact on oocyte and early mammalian embryo developmental competency.
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Recently, Yousif et al. (2020), from our laboratory, investigated the dose-dependent
effects of OA up to 500 µM on developing mouse preimplantation embryos and observed
no significant impairments in blastocyst development at any tested dose. Cell
morphology at all preimplantation cell stages was unaffected as well (Yousif et al. 2020).
No differences were observed in ER stress mRNA transcript levels in OA-treated
embryos; but it was noted of that OA treatment significantly enhanced lipid droplet
accumulation (Yousif et al. 2020). These findings shine light on the underlying lipid
metabolism mechanism that may contribute to the protective effects of OA exposure on
various cell types including the preimplantation embryo.

1.10.3

The Effects of OA on Other Cell Types

OA is described to have beneficial effects to many cell types. For example, it is
protective against myocardial injuries, as demonstrated by Singh et al. (2020). After
myocardial damage, rats that were pre-treated with OA showed a significant
improvement in lipid profiles, as well as cardiac injury biomarkers compared to controls
(Singh et al. 2020). It was identified that pre-treatment with OA prior to myocardial
injury induction upregulated gene expression of a reactive oxygen species (ROS)
regulator, UCP-2, as well as increased antioxidant activity in the cardiac tissues (Singh et
al. 2020). One of the notable benefits of OA included its anti-tumor effects. In the search
of a healthier diet, the Mediterranean diet was proposed as a cancer risk-reducing diet,
due to its high content of antioxidant and anti-inflammatory properties from (though not
limited to) OA-rich foods (Mentella et al. 2019). The inclusion of high OA in the diet
significantly reduces the susceptibility to colon cancer in a male rat cancer model
(Schwartz et al. 2004). Rats that were fed high OA diet had less cancerous lesions in the
colon tissue compared to rats with low OA diet (Schwartz et al. 2004). It was further
explained that high OA content significantly lowered expression of COX-2, an
inflammatory marker, and increased apoptotic activity in the cancerous tissue (Schwartz
et al. 2004). The combination of high OA diet and an anti-tumor drug even showed
synergistic effects against colon cancer incidence, highlighting the advantages of
including OA intake as a therapeutic option (Schwartz et al. 2004). A literature search on
the anti-tumor effects of OA summarized the underlying effects of OA on oncogene
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expression (Carrillo et al. 2012). Notably, Menendez et al. (2005) identified that OA
suppressed the over-expression of HER2, an oncogene noted for progression and
metastasis of numerous human cancers, in breast cancer cell lines. The addition of OA to
Herceptin, a chemotherapy medication for cancer, had synergistic effects that reduced
Her-2 expression and enhanced apoptosis in breast cancer cells (Menendez et al. 2005).
These findings show strong support for the benefits of OA in cancer prevention and
tumor suppression. In the liver, OA plays an important role in normal hepatic
functioning. Inhibition of OA de novo synthesis in the liver, by genetic knockout of
hepatic lipogenesis protein SCD1, demonstrated low lipid accumulation with severe
hepatic damage in mice fed with low-fat diet (Flowers et al. 2006). These mice had
increased levels of bilirubin and bile acid in the serum, demonstrating cholestasis
phenotypes that are common in patients with jaundice and liver failure (Flowers et al.
2006). A follow-up analysis of gene expression in the liver identified an enhancement of
ER stress and inflammation that contributed to the hepatic damage observed in those
mice (Flowers et al. 2008). However, when supplemented with OA in the diet, hepatic
function was restored and lipid accumulation, except for plasma cholesterol levels,
returned to normal states (Flowers et al. 2006).

1.11 Palmitic Acid (PA) and Oleic Acid (OA) Co-treatment
1.11.1

PA and OA Co-treatment on Embryo Development

The protective ability of OA on embryo development has sparked interest in its effects
when presented with saturated fatty acids that are generally believed to be harmful.
Common consensus from the literature would suggest that a higher unsaturated-tosaturated fatty acid ratio should provide benefits to preimplantation embryo development.
In bovine oocytes, Aardema et al. (2011) investigated the effect of OA co-treatment with
saturated fatty acids, PA, and stearic acid (SA), on oocyte developmental competency
and lipid metabolism. It was reported that although PA and SA, individually, had adverse
effects on oocyte maturation in a dose-dependent manner, the addition of OA with each
saturated fatty acid alleviated the adverse effects and restored developmental competency
(Aardema et al. 2011). Furthermore, the combination of OA with each saturated fatty acid
showed significantly greater lipid droplet accumulation (size and number), in bovine
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oocytes than compared to PA and SA individually, highlighting the change in lipid
storage as a potential mechanism of the compensatory effects of OA (Aardema et al.
2011). The hypothesis that OA counteracts PA-induced effects are also supported in
murine embryos. Yousif et al. (2020) reported that incubation of mouse embryos in PA
and OA combined, supplemented culture medium restored blastocyst development to
control levels, compared to the significant developmental arrest observed in the PA-alone
group. Furthermore, the rescuing effects of OA in the combination treatment beneficially
affected ER stress pathway gene expression at the IRE1-α and PERK arm, lipid
metabolism, as well as mitochondrial ROS levels, by reversing PA-induced effects to
control levels (Yousif et al. 2020). Although OA is well-recognized for its protective
effects, its abilities may be limited when exposed to a high proportion of saturated fatty
acids. The study by Van Hoeck et al. (2011) investigated the effect of PA, SA, and OA
co-treatment on bovine oocyte and embryo development. When bovine oocytes were
treated with PA, SA, and OA in combination at a high saturated-to-unsaturated fatty acid
ratio prior to fertilization, blastocyst development was significantly lower than the
supplemented control (Van Hoeck et al. 2011). Additionally, the total cell number and
apoptotic cell index of those embryos were significantly lower and higher, respectively,
in the co-treatment (Van Hoeck et al. 2011). These findings support that OA can, in fact,
counteract the effect of PA in early embryo development; however, the protective
mechanism can still be overwhelmed, or even fail, when exposed to especially high
proportions of saturated fatty acids.

1.11.2

PA and OA Co-treatment on Other Cell Types

The effects of PA and OA co-treatment on hepatocytes have been extensively studied as
the liver is the main site of lipid metabolism. Chen et al. (2018) investigated the
protective effects of PA and OA combination treatment on hepatocytes. In human HepG2
cells, the authors reported that in vitro culture with OA alleviated the PA-induced impact
on hepatocyte viability at a 2:1 PA-to-OA molar ratio, which the presence of OA in PA
culture media significantly reduced apoptosis compared to PA-alone treatment (Chen et
al. 2018). Though, the benefit of OA inclusion was time-dependent where OA
supplementation after 24 hours of PA-only treatment was unable to rescue hepatocyte
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viability to control levels (Chen et al. 2018). It was suggested that OA exerts its
protective mechanism on PA-induced effects by lowering cell stress, inflammation, and
restoring mitochondrial functions (Chen et al. 2018). These findings were paralleled by
primary rat hepatocytes under the same molar ratio of PA and OA co-treatment in the
same study (Chen et al. 2018). Another major site of lipid metabolism is the skeletal
muscle. A study by Peng et al. (2011) reported the changes in lipid metabolism by PA
and OA treatments, in vitro, in mouse C2C12 myocytes. Like other studies, the authors
reported that OA treatment resulted in larger lipid droplets than PA treatment alone (Peng
et al. 2011). The outcomes indicated that significantly more PA was stored as TAG lipid
droplet in the presence of OA compared to PA-alone treatment (Peng et al. 2011).
Consistently, the conversion of PA into phospholipids and diacylglycerol (DAG) lipid
droplets was significantly lowered in the presence of OA (Peng et al. 2011). Along with
the findings that OA protects against ER stress in myocytes caused by PA effects, it was
stated that OA prevents lipotoxicity of myocytes by mediating ER stress through alternate
processing of excess lipids (Peng et al. 2011).

1.12 Cell Stress in Preimplantation Embryos
During embryogenesis, the growing embryo experiences various types of stress. These
stress factors can be categorized into two main categories, local and environmental stress.
The source of local stress on the embryo includes oxidative stress and inflammation
among many others. Whereas environmental stress factors include maternal hormone and
toxins (Puscheck et al. 2015). Embryo manipulation and growth in vitro also poses
additional stress during embryogenesis through handling and culture conditions, to name
a few. Ultimately, the embryo must utilize its capacity to adapt and offset exposure to
stressors to achieve and maintain high developmental capacity.
One of the main factors for stress during embryogenesis is energy expenditure. A large
amount of energy is required to support the exponential growth in cell number and
division during the early cleavage stages. After fertilization, the developing embryo at the
early stages utilize ATP from mitochondrial oxidative phosphorylation of pyruvate
(Dumollard et al. 2007). Pyruvate is supplied by surrounding cumulus cells and follicular
fluid to be taken up into the oocyte mitochondria (Bradley and Swann 2019). It is not
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until after compaction at the 8-cell stage, in the mouse, that energy production from
glucose via glycolysis is favored over pyruvate oxidation, with accompanying increased
oxygen consumption (Leese and Barton 1984). Preimplantation embryo oxygen
consumption is significantly lower in the early cleavage stages compared to the blastocyst
stage, indicative of a low level of aerobic metabolism at the early stages (Leese et al.
2016). The quiet embryo hypothesis proposed by Leese (2002) suggests that instead of
inactivity, mitochondria of the embryo at early stages function at a minimal level to
provide just enough energy to meet its energy requirements. This hypothesis has been
widely accepted as it nicely provides a sound reason behind low energy metabolism in
early embryos – to minimize reactive oxygen species (ROS) production from direct
pyruvate oxidation (Bradley and Swann 2019). ROS is an oxygen substrate that can cause
oxidative damage to organelles and DNA. A study by Dumollard et al. (2017) reported
that under high pyruvate environment in culture, mouse embryo blastocyst development
was negatively impacted. It is further explained that the excess source of energy
metabolite pyruvate may contribute to ROS production that disrupts blastocyst
development (Dumollard et al. 2017).
Another source of energy expenditure comes from fatty acid oxidation. Fatty acids are
taken up by embryos at the earliest stages as an energy source. In fact, fatty acids are
taken up as early as an oocyte through the surrounding cumulus cells and follicular fluid.
These lipids are converted into TAG by diacylglycerol acyltransferase (DGAT) enzyme
to be stored as lipid droplets in the oocyte and embryo in the cytoplasm and endoplasmic
reticulum (ER) (Bradley and Swann 2007). A study applied to porcine preimplantation
embryos reported a significant decrease in lipid droplet volume at the blastocyst and lateblastocyst stages compared to other developmental stages (Romek et al. 2009), indicating
a potential utilization of fatty acids as an energy source at the blastocyst stage.
Although embryos can metabolize lipids, a high fat environment is detrimental to
preimplantation embryo development, as mentioned in the previous sections. Follicular
fluids of mothers with high BMI levels tend to have higher concentrations of free fatty
acids and triglycerides (Robker et al. 2009). High lipid contents taken up by the oocytes
from the follicular fluid produce ROS and lipid peroxides that lead to lipotoxicity
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(Igosheva et al. 2010). Many organelles including the mitochondria and ER experience
structural remodeling and dysfunction due to lipotoxicity that ultimately induce apoptotic
cell death (Wu et al. 2010). Lipotoxicity-induced dysregulation of the ER can also
promote an imbalance in ER protein folding, resulting in the accumulation of unfolded
proteins and activation of ER stress response mechanisms. The unfolded protein response
(UPR) is activated to maintain ER homeostasis by removing unfolded proteins and
preventing further protein production (Lin et al. 2019). Under prolonged ER stress, cells
may opt to activate apoptosis to eliminate additional cell stress or perhaps autophagy
(Lee et al. 2015), to restore ER homeostasis.

1.13 Autophagy
Autophagy is a cellular degradation pathway that is highly conserved in eukaryotes
(Ravanan et al. 2017). In brief, it is a pathway in which cytoplasmic components in the
cells are degraded by lysosomes for reuse in other cellular functions (Ravanan et al.
2017). Autophagy serves many different functions, including organelle clearance,
regulation of development, as well as stress adaptation (Mizushima 2005). Autophagy is
widely recognized as a pro-survival mechanism due to its protective functions and its
involvement with mediating cell stress, specifically with ER stress (Lee et al. 2015). As
mentioned, ER stress activates the UPR pathway that aims to maintain ER homeostasis.
The UPR functions to upregulate the activity of protein degradation in the ER but would
also upregulate autophagy to clear the ER from the accumulation of misfolded or
unfolded proteins. Ogata et al. (2006) reported that inhibition of ER stress at the IRE1
and JNK pathway inhibited ER stress-induced autophagy in human neuroblasts cells,
suggesting a strong link between ER stress and autophagy in cell survival. In addition to
the ER stress mechanism mentioned earlier, autophagy can be triggered by many other
factors like nutrient starvation and ROS buildup (Mizushima 2007). Autophagy can be
described as a three-step process consisting of initiation, maturation, and degradation.

1.13.1

Initiation of Autophagy: Autophagosome Formation

Under normal conditions, autophagy induction is negatively regulated by the mammalian
target of rapamycin (mTOR), in which mTOR phosphorylates its downstream UNC-51-
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like kinase 1 (ULK1) complex to block autophagy initiation (Lee et al. 2015). Nutrientrich environments and growth factor signaling converge on mTOR activation to promote
growth (Saxton and Sabatini 2017). Summary of the process of inactivated autophagy is
displayed in figure 2.
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Figure 2. Summary of inactivated autophagy under nutrient-rich conditions.
Under nutrient-rich conditions, the ratio of ATP to AMP is high, which enables growth
factor signaling to converge on mTOR activation. The activation of mTOR protein
phosphorylates ULK1 complex and deactivates ULK1, inhibiting autophagy. Created
with BioRender.com.
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However, under nutrient-deprived or stress conditions, mTOR activity is suppressed (Lee
et al. 2015). For example, the low energy condition is reflected by a high AMP-to-ATP
ratio, which results in AMP-activating protein kinase (AMPK) inhibiting mTOR and
activation of autophagy (Lee et al. 2015). Inhibition of mTOR dephosphorylates
downstream ULK1 complex, leading to its activation. Activated ULK1 complex, along
with autophagy-related protein ATG13, phosphorylate and activate downstream effectors
of the class III phosphatidylinositol 3-kinase (PI3K) complex (Melia et al. 2020). The
PI3K complex consist of factors like activating molecule in Beclin-1-regulated autophagy
1 (AMBRA1) and Beclin-1 (Bcln1). AMBRA1 is the connector protein that binds Beclin1 and PI3K at the dynein complex until autophagy is initiated (Melia et al. 2020). The
activation of ULK1 phosphorylates AMBRA1 to allow translocation of the PI3K
complex to the ER for autophagosome formation (Cianfanelli et al. 2015). Additionally,
Ambra1 regulates autophagy by stabilizing the activity of ULK1 (Nazio et al. 2013).
Bcln-1 is an important mediator for autophagy as the chemical induction of Bcln-1
cleavage by caspase-3 inhibits autophagy as previously reported by Zhu et al. (2010).
The activation of Bcln-1 dissociates itself from B-cell lymphoma 2 (Bcl-2), which
activates Bcl-2 for anti-apoptotic functions to support the pro-survival nature of
autophagy

(Hill

et

al.

2018).

The

activation

of

PI3K

complex

produces

phosphatidylinositol-3 phosphate (PI3P), which initiates the nucleation of a phagophore,
a pre-autophagosome structure at the ER (Noda et al. 2010). The elongation of the
phagophore involves recruitment of lipids to extend and form a double membrane
autophagosome. The calculation by Melia et al. (2020) estimated that over 100 million
lipid molecules are required per cell to support autophagosome formation. The presence
of PI3P on the autophagosome membrane also recruits protein complexes for membrane
elongation (Melia et al. 2020). The ATG5-ATG12-ATG16 complex is recruited to
specific sites on the autophagosome membrane, though these binding sites are of unclear
origin. Mizushima et al. (2001) identified these sites as crescent-like membrane-bound
compartments in autophagosomes where ATG5 binds; nevertheless, very little is known
about these structures. The ATG5-ATG12-ATG16 complexes on the autophagosome
membranes contribute to autophagosome curvature and to recruit activated microtubuleassociated protein light chain 3 (LC3) (Melia et al. 2020). LC3 is a marker for
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autophagosome formation as it binds to both the inner and outer membranes of the
autophagosome (Kabeya et al. 2000). LC3 is first translated in the cell as a precursor.
Through ATG4 processing at the carboxylic terminal, LC3 is activated into its cytosolic
form LC3-I (Agrotis et al. 2019). With ATG3 and ATG7, a phosphatidylethanolamine
(PE) is conjugated onto LC3-I to create LC3-II, which can then be recruited onto
autophagosome membranes by the ATG5-ATG12-ATG16 complex (Agrotis et al. 2019).
LC3-II is widely accepted as a marker for autophagosome formation because its
generation is initiated by autophagy induction, and it is degraded along with
autophagosome contents (Singh and Bhaskar 2019). The elongation of the phagophore
eventually seals the membranes and creates an autophagosome.
Autophagosome contents are quite random and non-discriminatory (Ravanan et al. 2017).
However, some selective degradation products have been identified. It was proposed that
LC3-II in the inner membrane can interact with and recognize P62/SQSTM1 adaptor
proteins that bring in ubiquitinated proteins for degradation (Lamark et al. 2017).
Additionally, neighbour of BRCA1 gene 1 (NBR1) is described to direct ubiquitinated
protein aggregates into autophagosomes by binding to LC3-II of the inner membrane,
independent of the P62 mechanism (Kirkin et al. 2009). Summary of the process of
autophagosome formation is displayed in figure 3.
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Figure 3. Summary of autophagosome formation.
Under nutrient-deprived conditions, the ratio of AMP to ATP is high, it activates AMPK
to inhibit mTOR activity. Inhibition of mTOR prevents phosphorylation of ULK1
complex and activates autophagy. Activated ULK1, along with ATG13, phosphorylate
AMBRA1 that is attached to the microtubule network via a dynein motor unit. The
activation of autophagy also dissociates Bcln1 from Bcl-2, freeing Bcl-2 to prevent
apoptosis and allow Bcln1 to join AMBRA1 and the rest of PI3K complex at the
microtubule network. The phosphorylation of AMBRA1 frees the entire PI3K complex to
translocate to the ER. Once at the ER, the PI3K complex produce PI3P that initiates
nucleation of a phagophore. Then, the ATG5-ATG12-ATG16 complex associates and
attaches onto the phagophore as the phagophore elongates to form an autophagosome.
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The ATG5-ATG12-ATG16 complex then recruits activated LC3-II to both the outer and
inner membranes of the autophagosome. Processing of LC3 via ATG proteins and
lipidation with PE activates LC3 into LC3-II. LC3-II proteins on the inner membrane
recruit p62 and NBR1 attached to ubiquitinated proteins to bring in autophagosome
contents. As contents are directed into the phagophore, elongation of the membrane
eventually seals the membrane and creates an autophagosome. Created with
BioRender.com.
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1.13.2

Autophagosome Maturation: Autolysosome

After the completion of the autophagosome, fusion with a lysosome is necessary for
degradation of the contents. To do so, autophagosomes must dissociate from the ER and
enter the cytoplasm to interact with a lysosome. The transport of an autophagosome in a
mammalian cell requires the cytoskeletal microtubules (Zhao and Zhang 2019).
Interestingly, in primary mouse dorsal root ganglion neurons, Maday et al. (2012)
reported the unidirectional movement of distal autophagosomes towards the cell body via
dynein units on microtubules. Another study by Köchl et al. (2006) chemically disrupted
the microtubule network in primary rat hepatocytes and found a lower percentage of
mature autophagosomes than control, as reflected by a lower co-localization rate of
autophagosomes and lysosomes. These studies describe a role for microtubule networks
in autophagosome transport. Two different hypotheses were proposed for the attachment
of the autophagosomes to microtubules. One being that LC3-II on the outer
autophagosome membrane directly binds onto microtubules, as antibodies against LC3-II
N-terminus prevented autophagosome trafficking towards lysosomes (Kimura et al.
2008). Another hypothesis is that Rab7, a GTPase protein located on the late endosomes
and lysosomes, recruits the dynein motor units attached to autophagosomes and thus
contributes to its transport towards lysosomal structures (Jordens et al. 2001); however,
evidence is scarce.
The autolysosome defines the structure of the autophagosome after lysosome fusion. This
fusion occurs in a stepwise fashion, with acquisition of different lysosomal membrane
proteins and hydrolases at each step (Zhao and Zhang 2019). First, autophagosomes fuse
with early endosomes. Fusion of autophagosomes with early endosomes is required prior
to fusion with lysosomes for proper content degradation to occur during autophagy;
however, this fusion does not result in the formation of an acidic lumen or for the
necessary proximity for degradation by proteases (Razi et al. 2009). Next,
autophagosomes fuse with late endosomes and lysosomes. The fusion between
autophagosomes and lysosomes require Rab GTPases, membrane-tethering proteins, and
soluble N-ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) proteins
(Zhao and Zhang 2019). Rab7 protein is the main coordinator of the fusion process in
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which it localizes onto specific sites of the autophagosome membrane (Zhao and Zhang
2019). Then, membrane-tethering proteins called the homotypic fusion and vacuolar
protein sorting (HOPS) complex are recruited to Rab7 sites to attach the SNARE proteins
on both the autophagosome and lysosome for the fusion event (Ganley 2013). The
interaction of the SNARE proteins brings the autophagosome and lysosome together,
allowing the fusion event to create the autolysosome. Summary of the process of
autophagosome maturation is displayed in figure 4.
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Figure 4. Summary of autophagosome maturation.
After autophagosome formation, the autophagosome is transported from the ER to the
lysosome for maturation into an autolysosome. An autophagosome is transported through
the cell via the microtubule network with a dynein motor protein. The autophagosome is
first fused with an early endosome. Then, the autophagosome is transported towards the
lysosome as Rab7 GTPase on the lysosome recruits the dynein protein. When the
autophagosome is in near proximity of the lysosome, Rab7 GTPase localize to the HOPS
complex and recruits SNARE proteins to attach the autophagosome with the lysosome.
After attachment, hydrolysis of the GTP to GDP on the Rab7 GTPase provides energy for
the fusion of autophagosome and lysosome, creating an autolysosome. Created with
BioRender.com.
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1.13.3

Autophagosome Degradation with Lysosomes

After fusion of the autophagosome with a lysosome, autophagosome contents are
degraded by lysosomal hydrolases. This degradation process degrades organelles and
proteins into monomeric units like lipids and amino acids (Mizushima 2007). The
degraded contents are then exported out into the cytoplasm for reuse in other cellular
functions (Mizushima 2007). Little is known about lysosomal transporters in mammalian
cells. So far, only the lysosomal amino acid transporter 1 (LYAAT-1) has been identified
for the exportation of amino acids from lysosome to the cytoplasm (Sagné et al. 2001).
Summary of the process of autophagosome degradation is displayed in figure 5.
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Figure 5. Summary of autophagosome degradation.
After the fusion event, autophagosome contents are degraded by lysosomal enzymes into
monomeric units. The monomeric units are then transported out of the autolysosome via
transporters like LYAAT-1. The monomeric units released into the cytosol are then
reused for other cellular functions, like protein production, membrane formation, and cell
maintenance. Created with BioRender.com.
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1.14 Autophagy in Preimplantation Embryos
Autophagy was first reported to be essential for embryo preimplantation development by
Tsukamoto et al. (2008). It was discovered that oocyte fertilization induces autophagy,
and this induction is important for zygotic genome activation (ZGA) where maternal
proteins are degraded as zygotic proteins are synthesized (Tsukamoto et al. 2008). In
mouse embryos, deficient autophagic mechanisms arrest embryos at the 4- to 8-cell
stages in vitro; whereas in vivo generation of Atg5-null mice die within one day of
delivery (Tsukamoto et al. 2008). A study by Lee et al. (2011) investigated the effects of
autophagy modulators on mouse preimplantation development. Under rapamycin
(autophagy inducer) treatment, mouse embryos significantly increased apoptosis and
displayed a significantly lower cell number than control, though blastocyst development
was not impacted. Treatment of mouse embryos with 3-methyladenine (3-MA), an
autophagy inhibitor, also resulted in a significant increase in apoptosis and lowered total
cell count (Lee et al. 2011). Additionally, blastocyst development was decreased
compared to control (Lee et al. 2011). Cell fate determination as reflected by ICM cell
count was significantly higher after autophagy activation (Lee et al. 2011). These
findings support that autophagy plays an essential role in early preimplantation embryo
development, specifically in cell fate determination, achieving proper developmental
competency, and even survival through the developmental stages. Some benefits
following modulation of the autophagy pathway have been revealed in studies. For
example, acute induction of autophagy with rapamycin significantly increased blastocyst
development, TE cell number, as well as viability in in vitro produced bovine embryos
(Song et al. 2012). Short-term induction of autophagy also relieved bovine embryos from
ER stress, which may have contributed to the improvement in blastocyst viability
observed in the study (Song et al. 2012). So far, no consensus is established regarding
which direction of autophagy modulation is of most benefit for successful
preimplantation embryo development and pregnancy. However, studies have highlighted
the ability of autophagy modulation to improve early embryo development.
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1.15 Autophagy in other cell types
Generally, autophagy acts to maintain homeostasis in a cell but its function and effects
vary considerably across cell types and varying environmental conditions. Mizushima
and Komatsu (2011) summarized the roles of autophagy in different organ systems.
Autophagy exerts its function, ranging from preventing protein aggregation in the brain
to preventing degeneration in the liver; as well as adaptation of heart cells to
hemodynamic stress, to adaptation of pancreatic cells to high-fat diet, among many others
(Mizushima and Komatsu 2011). Autophagy also has cytoprotective effects in various
health conditions. In hepatocytes, a common genetic mutation of the hepatic
glycoprotein, α-antitrypsin Z (α-ATZ), results in the accumulation of α-ATZ in the ER of
the hepatocytes that eventually leads to chronic liver disease and even cancer (Kamimoto
et al. 2006). It was suggested that autophagy plays a role in the clearance of the mutant αATZ protein from the ER in addition to other degradation pathways like the ubiquitinproteasome system, and it contributes to alleviating hepatic injury from α-ATZ protein
buildup (Kamimoto et al. 2006). In neurons, the neurodegenerative Huntington disease
results from the polyglutamine tract mutation which accumulates huntingtin proteins as
protein aggregates (Ravikumar et al. 2004). The study by Ravikumar et al. (2004)
reported that mutation in the huntingtin protein induces autophagy in human and mouse
brains as well as cell models of Huntington disease to clear toxic mutant fragments. The
treatment of rapamycin, an inducer of autophagy, slows neurodegeneration in flies
expressing the mutant huntingtin protein and resulted in smaller and less aggregate
formation in a cell model expressing the mutant protein (Ravikumar et al. 2004). A
mouse model of the Huntington disease also resulted in better performance in behavior
and motor tasks when treated with a rapamycin analog compared to the placebo drug
(Ravikumar et al. 2004). These findings show the direct effects of autophagy in
neurodegenerative diseases and propose potential utilization of autophagy modulation as
means of therapeutic options.

1.16 Lipotoxicity and Autophagy
The relationship between lipotoxicity and autophagy is a new research focus in that the
first article investigating a connection between the two first appeared in 2009. The first
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investigation assessed the effects of lipids on autophagy in skeletal muscle cells, though
no effects were identified in altering apoptosis, autophagy, and lysosomal pathways
(Turpin et al. 2009). Studies then shifted their interests in autophagic pathways of liver
and pancreatic cells and identified that not only does autophagy plays a role in regulating
cell homeostasis, it also counteracts the lipotoxicity-induced stress in cells of diabetic
mouse models, suggesting a potential protective mechanism of autophagy against
lipotoxicity (Choi et al. 2009). However, evidence was conflicting as prolonged induction
of autophagy can affect cell survival (Las and Shirihai 2010). Recent research efforts
suggest that autophagy alleviates lipotoxicity effects, especially in the brain and the liver.
In the brain, elevated fatty acid level accelerates oxidative stress that is associated with
neurological disorders; but autophagy protects against this effect by eliminating ROSgenerating organelles (Giordano et al. 2013). The study by Carotti et al. (2020) identified
that non-alcoholic fatty liver disease (NAFLD) implicates lipophagy, a subset type of
autophagy that specifically regulates lipid droplet degradation. This disruption is
correlated with the abundance of autophagic marker expression of P62 as well as fibrosis
stage in human and mouse with NAFLD (Carotti et al. 2020). Furthermore, exposure of
hepatocytes to PA, triggered mTOR activation and induced expression of downstream
targets that inhibit autophagy, whereas OA exposure had no effect on mTOR activity
(Carotti et al. 2020). mTOR inhibitors initiate autophagy and attenuate PA-induced
effects on hepatocytes including apoptotic cell death (Chen et al. 2020). It is therefore
evident that lipotoxicity in hepatocytes following exposure to PA can be mediated by
autophagic mechanisms.

1.17 Rationale
Previous studies have identified autophagy as an essential component to regulating cell
homeostasis, cell growth and preimplantation development. Autophagy also has a
protective mechanism against cytotoxic lipotoxicity in various cell types. Mouse
preimplantation embryos display a dose dependent reduction in blastocyst development
when exposed to PA treatment in culture and this effect of PA is reversed when cotreated with OA. Evidence suggests that autophagy may be beneficial in offsetting the
negative effects of a high fat environment and may play a role in early preimplantation
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embryo development where embryos are highly susceptible to environmental factors. To
date, although some have investigated the effects of elevated NEFA exposure on
autophagy in general, very few investigations were done specifically for the period of
mouse preimplantation development.

1.17.1

Objectives and Hypotheses

Previous study from our lab group (Yousif et al. 2020) identified that NEFA exposure
affects early mouse embryo development, which included PA-induced ER stress and
impairment of blastocyst development. OA had no effects on development but reduced
mitochondrial ROS and enhanced lipid droplet accumulation. It was also reported that the
addition of OA to treatment media reversed PA-induced effects. The protective
mechanisms of OA against PA effects are not exclusive to early embryo development but
are observed in other cell types as well. My research project aimed to understand the
underlying autophagic mechanisms impacted by the exposure to high levels of NEFA
during early mouse preimplantation embryo development in vitro.

1.17.2

Specific Aims

1) To assess autophagy in NEFA-treated mouse embryos throughout preimplantation
development. Autophagic markers were investigated in mouse preimplantation
embryos after NEFA exposure times of 18, 24, 30, 40, and 48 hours.
2) To assess autophagosome formation in NEFA-treated mouse preimplantation
embryos. Autophagic markers were investigated after NEFA exposure for 40
hours with chloroquine (autophagy inhibitor) treatment at the last two hours of
incubation.
3) To assess autophagosome maturation and degradation in NEFA-treated mouse
embryos. Autophagosome-lysosome localization as well as lysosomal activity was
investigated after NEFA exposure for 40 hours.
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1.17.3

Hypothesis

Overall, it was hypothesized that NEFA-induced lipotoxicity dysregulates autophagic
mechanisms in mouse preimplantation development. Specifically, PA will disrupt
autophagosome formation while the addition of OA will negate lipotoxic effects to
enhance overall developmental success.
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Chapter 2

2

Materials and Methods

2.1 Animals and Ethics Approval
All experiments were conducted using CD-1 mice from Charles River Laboratories
(Senneville, QC). All mice were handled in accordance with the Canadian Council on
Animal Care and Western University’s Animal Care and Use Policies (Protocol # 2018075; Appendix E). Mice were housed in conventional housing with 12-hour light-dark
cycle and access to food and water ad libitum.

2.2 Mouse Embryonic Stem Cell (mESC)
R1 wild-type mouse embryonic stem cells (mESC) derived from CD1 mouse embryos
(Nagy et al. 1993) were purchased from SickKids Hospital (Toronto, ON).

2.3 NEFA Preparation
Palmitic acid (PA) and oleic acid (OA) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Free fatty acid-free (FFA-free) BSA was purchased from Sigma-Aldrich (St.
Louis, MO, USA). FFA-free BSA was dissolved in PBS overnight and filter sterilized to
create a 20 % BSA stock solution. The stock solution was stored at -20 °C until use. PA
and OA stock solutions were prepared by solubilizing each fatty acid in RNAase-free
water using NaOH at 70 °C to a stock concentration of 20 mM. The 20 % BSA solution
was used to conjugate PA and OA stock solutions in a 2:1 fatty acid-to-BSA molar ratio
to a final concentration of 500 µM, then stored in 4 °C until use.

2.4 Embryo Culture
All experimental treatments were prepared with potassium simplex optimization media
with amino acids (KSOMaa, Caisson Labs, Smithfield, UT). BSA culture media was
prepared with the stock 20 % BSA solution to 1.5 % BSA in KSOMaa media. Culture
dishes of 35 mm diameter (Corning, NY, USA) were used for embryo culture. Dishes
were prepared with 20 µL droplets of the treatment media and the treatment droplets
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were covered with embryo-grade mineral oil (LiteOil, LifeGlobal, Guilford, CT, USA).
Pools of embryos were placed into the appropriate treatment medium at the density of 1
embryo per µL of treatment medium. After which, embryos were cultured in vitro under
5 % CO2, 5 % O2, and 90 % N2 environment at 37 °C for up to 48 hours.
Experiment 1: To assess autophagy in NEFA-treated embryos throughout
preimplantation development
Experiment 1 identified the effects of NEFA exposure on early embryo autophagy.
Embryos were treated in vitro with 100 μM PA, 250 μM OA, 100 μM PA and 250 μM
OA, or KSOMaa medium alone (control) for 18, 24, 30, 40, and 48 hours.
Experiment 2: To assess autophagic flux in NEFA-treated embryos
Experiment 2 determined the changes in autophagic flux of early embryos under NEFA
treatment. Embryos were treated in vitro with 100 μM PA, 250 μM OA, 100 μM PA and
250 μM OA, or KSOMaa medium alone (control) for 40 and 48 hours, with the addition
of 75 μM of chloroquine (CQ) for 2 hours at the end of incubation period.
Experiment 3: To assess autophagosome-lysosome interaction in NEFA-treated mouse
embryos
Experiment 3 determined the changes in autophagosome-lysosome interaction of early
embryos under NEFA exposure. Embryos were treated in vitro with 100 μM PA, 250 μM
OA, 100 μM PA and 250 μM OA, or KSOMaa medium alone (control) for 40 hours.

2.5 mESC Culture
R1 mouse embryonic stem cells (mESC) were maintained on 0.2 % gelatin-coated culture
dishes. mESC culture medium consisted of KnockOut DMEM/F12 medium (49 %,
Gibco, Thermo Fisher Scientific, USA), Neurobasal medium (49 %, Gibco, Thermo
Fisher Scientific, USA), GlutaMax Supplement (1 %, Gibco, thermo Fisher Scientific,
USA), 2-mercaptoethanol (0.1 %, Gibco, Thermo Fisher Scientific, USA), N2
supplement (0.5 %, 100X, Gibco, Thermo Fischer Scientific, USA), B27 supplement (1
%, 50X, Gibco, thermo Fisher Scientific, USA), mouse leukemia inhibitory factor (mLIF,
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0.01 %, MilliporeSigma, USA), PD0325901(0.01 %, 39-C68; Reagents Direct, Encinitas,
CA, USA) and CHIR99021 (0.03 %, 27-H76; Reagents Direct, Encinitas, CA, USA).
mESC medium was replaced daily and monitored for spontaneous differentiation. All
experiments were cultured under 5 % CO2 environment at 37 °C.
Supplementary experiment: To assess autophagy in NEFA-treated mouse embryonic
stem cells
The supplementary experiment evaluates the changes in autophagy after NEFA exposure
in mESC. mESC were treated with 1.5 % BSA (Cytiva, USA), 100 μM PA, 250 μM OA,
100 μM PA and 250 μM OA, or mESC culture medium alone (control) for 48 hours.

2.6 Mouse Superovulation and Mating
CD-1 female mice of 3-4 weeks old were gonadotrophin super-ovulated to prepare for
mating. Female mice received intraperitoneal (IP) injections of pregnant mare serum
gonadotrophin (PMSG, Merck Animal Health, Canada) at 5.0 IU to stimulate follicle
growth and maturation. After 48 hours, the mice received IP injections of human
chorionic gonadotrophin (hCG, Merck Animal Health, Canada) at 5.0 IU to stimulate
follicle maturation and ovulation. After hCG injections, the female mice were placed in a
cage with CD-1 male mice at 2:1 female-to-male ratio for mating overnight. The next
morning, female mice were checked visually for vaginal plugs, which serves as an
indication for successful mating. All female mice were returned to their original cage
until embryo collection was performed.

2.7 Embryo Collection
Embryos were collected from female mice 48 hours post-hCG injections (hpi). An hour
before collection, M2 flushing medium (Sigma-Aldrich, St. Louis, MO, USA) was
prepared in 3 mL syringes and warmed up to 37 °C. All female mice were sacrificed via
CO2 asphyxiation and oviducts were dissected out. The pair of oviducts dissected from
each mouse were placed into drops of warmed M2 flushing medium, under a heating
lamp and a warm water flask to maintain culture temperature. Under a light microscope,
oviducts were flushed using a needle (30 G) and a 3 mL syringe with warm M2 flushing
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medium to isolate embryos from the oviducts. A 9” Pasteur pipette (Fisherbrand, Thermo
Fischer Scientific, USA) was used to transfer embryos between media drops. Embryos
were removed from M2 flushing medium and then washed four times with KSOMaa
medium. After washing, 2-cell embryos were allocated to treatment groups at a density of
1 embryo per µL of treatment medium for the appropriate culture period.

2.8 Developmental Stage Analysis
After the designated culture period, embryos were collected for developmental stage
analysis. Embryos were viewed under a light dissecting microscope and the cell stage
progression for each embryo was classified. Embryos were identified as 2-cell, 4-cell, 8cell, morula, blastocyst stage, or degraded. Two-cell staged embryos consisted of two
equal-sized cells; 4-cell staged embryos consisted of three to four round cells; 8-cell
staged embryos consisted of five to eight round cells; morula stage embryos consisted of
more than eight cells after compaction; blastocyst stage embryos consisted of embryos
after cavitation; and degraded embryos consisted of at least one degraded cell. Figure 6
displays representative images of mouse embryos at different cell stages. Phase contrast
images of embryos at various cell stages were captured using Leica DM IL LED
microscope and Leica Application Suite V4.4 (Leica Microsystems, Canada).
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Figure 6. Representative images of mouse preimplantation embryo at each
preimplantation stage.
Representative images of mouse preimplantation embryos at the 2-cell, 4-cell, 8-cell,
morula, blastocyst stage, and degraded embryos. Inclusion criteria of each
preimplantation stage is included. Created with BioRender.com.
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2.9 mESC Cell Morphology
mESCs were viewed under a light microscope (Leica Microsystems, Canada) after the
designated incubation period for cell morphology. Digital images of mESC were captured
using a cell phone camera (Huawei P20) by Hailey Hunter.

2.10 RNA Extraction and Reverse Transcription (RT)
After embryo developmental stage analysis, mouse embryos were snap frozen at -80 °C
to preserve mRNA integrity in the cells. On the day of mRNA extraction, samples were
kept on ice to prevent thawing and degradation of mRNA samples. Arcturus PicoPure
RNA Isolation Kit (Applied Biosystems, Thermo Fisher Scientific, USA) was used for
RNA extraction of mouse embryos, according to manufacturer’s instructions. Exogenous
luciferase mRNA (Promega, USA) was added into RNA samples base on embryo number
(0.025 pg per embryo) as a reference gene for mRNA transcript analysis. An RNase-free
DNase set (Qiagen, KY, USA) was used to additionally remove genomic DNA from
RNA samples, according to manufacturer’s instructions. Reverse transcription was
performed with Sensiscript RT Kit (Qiagen, KY, USA), according to manufacturer’s
instructions, to reverse transcribe RNA to cDNA. cDNA samples from mouse embryos
were diluted to 0.5 to 1 embryo per µL with RNase-free water. cDNA samples were
stored at -20 °C until mRNA transcript detection.

2.11 Polymerase Chain Reaction (PCR)
cDNA samples were subjected to reverse transcription--polymerase chain reaction (RTPCR) to assess for cDNA quality. RT-PCR was performed for luciferase RNA control
(Luc, L4561, Promega Corporation, Madison, WI, USA) and histone H2A (Hist2h2aa1).
Each reaction consisted of 1 µL of cDNA sample with 24 µL of reaction mixture.
Reaction mixture was prepared with 10X PCR Buffer (0.1 %), MgCl2 (50 nM; 0.03 %),
dNTP (10 mM; 0.02 %), forward and reverse primers (0.004 % each), Taq polymerase
(0.004 %), and RNase free water. PCR was run in a thermocycler on these conditions: 94
°C for 2 minutes, then 44 cycles of: 94 °C for 30 seconds, 59 °C (Luc) or 61 °C
(Hist2h2aa1) for 30 seconds, and 72 °C for 1 minute, then 72 °C for 10 minutes. PCR
products were run on a 2 % agarose gel with ethidium bromide in 1X TAE running buffer
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for transcript detection of Luc and Hist2h2aa1. Luciferase forward primer (5’
TTGACAAGGATGGATGGCTAC

3’)

and

reverse

primer

(5’

TTCGGTACTTCGTCGTCCACAAAC 3’) and histone H2A forward primer (5’
CTCACCGCAGAGGTACTTGAG

3’)

and

reverse

primer

(5’

ATGCAGAAATTTGGTTGGTTG 3’) were obtained from Sigma-Aldrich (St. Louis,
MO, USA). An embryo pool and RNase-free water were used as a positive and negative
control, respectively. A DNA ladder (100 bp, Invitrogen, Thermo Fischer Scientific,
USA) was used to confirm the presence of cDNA transcript of Luc and Hist2h2aa1. Gel
electrophoresis was run at 115 V for 45 minutes. Gel was imaged using ChemiDoc XRS
system (Laird Lab, UWO) for transcript detection.

2.12 Quantitative Polymerase Chain Reaction (qPCR)
Quantitative polymerase chain reaction (qPCR) was performed to assess relative mRNA
transcript levels using TaqMan Universal PCR Master Mix (Applied Biosystems, Thermo
Fisher Scientific, USA), according to manufacturer’s instructions. A reaction mixture was
prepared with 2X TaqMan Universal PCR Master Mix (MM; 50 %), TaqMan primer
probes (5 %, Applied Biosystems, Thermo Fischer Scientific, USA), and RNase-free
water (45 %). Each reaction was plated in triplicates of 20 µL each with 1 µL of cDNA
into a 384-well plate. A non-transcript control of RNase-free water was included for each
gene. The plate was centrifuged at 2000 rpm for 2 minutes prior to qPCR reaction. The
BioRad CFX384 Touch Real-Time PCR Detection System was used to run the qPCR
reaction with the following conditions: 95 °C for 5 minutes, then 50 cycles of: 95 °C for
15

seconds

and

60

°C

for

(5’ACGTTCGTCACATCTCAT3’),

1

minute.
Becn1

Primer

probes

(Mm01265461_m1,

for

Luc

control

Thermo

Fischer

Scientific, USA), Atg3 (Mm00471287_m1, Thermo Fischer Scientific, USA), Atg5
(Mm00504340_m1, Thermo Fischer Scientific, USA), and Map1lc3b (Mm00782868_sH,
Thermo Fischer Scientific, USA) were used for analysis of autophagy-related genes.

2.13 Transcript Analysis
mRNA transcript levels were measured in cycle threshold (Ct) values through the CFX
Maestro 1.1 (Bio-Rad; USA). Relative mRNA abundance was quantified using the delta
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delta cycle threshold (2-ddCt) method. Transcript analysis was performed on Excel
(Microsoft, USA).

2.14 Immunofluorescence Staining
After the designated incubation period and developmental stage analysis, mouse embryos
were placed in 2 % paraformaldehyde in PBS for 30 minutes for fixation. Then, mouse
embryos were stored overnight in PHEM buffer (pH 6.9; Schliwa and van Blerkom 1981)
containing PIPES (60 mM), HEPES (25 mM), EGTA (10 mM), and MgCl2.H2O (1 mM)
to preserve structural integrity of actin filaments. The embryos were washed once with
PBS prior to blocking with a blocking buffer containing normal serum (5 %), Triton-X
100 (0.1 %), and NaN3 (0.02 %) in PBS. An antibody dilution buffer (ADB) was
prepared with normal serum (0.5 %), Triton-X 100 (0.05 %), and NaN3 (0.02 %) in PBS
for washes between incubation with antibody. Mouse embryos were washed with ADB
once, then incubated in primary antibody overnight. Three washes with ADB were
completed before placing embryos into secondary antibody for incubation overnight.
DAPI and Phalloidin was used to stain for cellular structures of cell nucleus and f-actin,
respectively. One hour of incubation with 4’,6-diamidino-2-phenylindole (DAPI; 0.1 %;
Sigma-Aldrich, St. Louis, MO, USA) and Phalloidin stain (5 %; Sigma-Aldrich, St.
Louis, MO, USA) was followed by two washes with ADB. Normal donkey serum
(Jackson ImmunoResearch, West Grove, PA, USA), anti-LC3A/LC3B polyclonal
antibody (Invitrogen, Thermo Fisher Scientific, USA), and Alexa Fluor 488 Donkey antiRabbit IgG secondary antibody (Invitrogen, Thermo Fisher Scientific, USA) were used
for protein localization of LC3-I and LC3-II.

2.15 Confocal Microscopy and Image Acquisition
Confocal microscopy was used to capture images of mouse embryos that were subjected
to immunofluorescence staining. Mouse embryos were mounted on a 35 mm glassbottom dish (MatTek, Ashland, MA, USA) with LiteOil-covered KSOMaa droplets for
imaging. Z-stack images were captured of each embryo at 5 µm interval between images,
using the 25X objective lens on a ZEISS LSM800 AiryScan confocal microscope
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(Schulich Imaging Core Facility, UWO). Images for all treatment groups within the same
replicate were captured using the same laser strength and intensity settings.

2.16 Image Analysis
Images captured from confocal microscopy were processed through ZEISS ZEN 3.1
(blue edition; Carl Zeiss Microscopy, Germany) for image export. Puncta structures were
measured using the “analyze particle” function of ImageJ (National Institutes of Health,
USA) based on pixel area of 9 pixel2. Cell numbers were counted manually. Colocalization experiment measured overlapping signal from multi-channel images via the
RG2B co-localization plug-in (Mauer 2004) on ImageJ. Fluorescence intensity was
analyzed through ilastik (1.3.3; open source) and intensity was measured in arbitrary
units.

2.17 Protein Extraction and Quantification
2.17.1

Protein Extraction and Quantification of Mouse Embryos

Protein extraction and quantification were carried out prior to detecting protein
abundance. Mouse embryos were snap frozen at -80 °C with 100X protease inhibitor (1
%; Calbiochem, MilliporeSigma, USA) and 100X phosphatase inhibitor (1 %;
Calbiochem, MilliporeSigma, USA) in Pierce RIPA buffer (Thermo Fisher Scientific,
USA) to lyse cells and release proteins from the embryos. Extracted protein samples from
mouse embryos were not quantified to measure total protein concentration due to the low
protein abundance in the embryos. All extracted proteins were used for western blot in
mouse embryo experiments.

2.17.2

Protein Extraction and Quantification of mESC

After incubation period, mESCs were washed briefly with PBS before collecting cells for
protein extraction. Pierce RIPA buffer (Thermo Fisher Scientific, USA) was prepared
with 100X protease inhibitor (1 %; Calbiochem, MilliporeSigma, USA) and 100X
phosphatase inhibitor (1 %, Calbiochem, MilliporeSigma, USA) then added to the
mESCs for collection with a cell scraper. mESCs collected were snap frozen at -80 °C
before sonication. mESCs were disrupted with a sonicator (Misonix S-4000 Sonicator,
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Qsonica, USA) at 30 A for 5 rounds of one second each to extract cell lysate. Cell lysates
were then quantified using a BCA assay with the Pierce BCA Protein Assay Kit (Thermo
Scientific, Thermo Fischer Scientific, USA) according to manufacturer’s instruction. The
SpectraMax M5 microplate reader (Molecular Devices, USA) and SoftMax Pro 5.2
software (Molecular Devices, USA) were used to measure total protein concentration of
the cell lysate at 562 nm.

2.18 Western Blot
2.18.1

Sample Preparation of Mouse Embryos

Protein lysates derived from mouse embryos were added with NuPAGE 4X LDS sample
buffer (25 %; Invitrogen, Thermo Fischer Scientific, USA) and NuPAGE 10X reducing
agent (10 %; Invitrogen, Thermo Fischer Scientific, USA). Then, samples were warmed
to 70 °C for 10 minutes to unfold extracted proteins.

2.18.2

Sample Preparation of mESC

Protein lysates derived from mESCs were added with NuPAGE 4X LDS sample buffer
(25 %; Invitrogen, Thermo Fischer Scientific, USA), NuPAGE 10X reducing agent (10
%; Invitrogen, Thermo Fischer Scientific, USA), and biology-grade water (Cytiva, USA)
to arrive at a concentration of 15 µg of protein per sample. Then, protein samples were
heated at 70 °C for 10 minutes to unfold extracted proteins.

2.18.3

Polyacrylamide Gel Electrophoresis (PAGE) and Protein
Transfer

Polyacrylamide gel electrophoresis (PAGE) was conducted to separate whole protein
samples. Protein samples from mouse embryos or mESCs (15 µg protein in 20 µL
sample) were separated in a NuPAGE 12 % Bis-Tris Mini Protein Gel (Invitrogen,
Thermo Fischer Scientific, USA) in NuPAGE 1X MOPS SDS Running buffer
(Invitrogen, Thermo Fischer Scientific, USA). NuPAGE Antioxidant (Invitrogen,
Thermo Fischer Scientific, USA) was added into running buffer to maintain protein
structure. The BLUelf Prestained Protein Ladder (FroggaBio, Concord, ON, Canada) was
used to monitor protein separation based on molecular weight. Gel electrophoresis was
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run at 75 V for 10 minutes then at 130 V for 1.5 hours. Separated protein samples from
gel electrophoresis was transferred onto a PVFD membrane in 1X tris-glycine-methanolbased transfer buffer. Protein transfer was run at 100 V for 2 hours.

2.18.4

Ponceau S Staining and Antibody Incubation

Ponceau S was used to stain for total protein on PVDF membranes after protein transfer.
For immunological detection, PVDF membranes were first blocked with 5 % BSA
(Cytiva, USA) in 1X TBST (0.01 % Tween-20) for an hour and then incubated with
primary antibody overnight. Membranes were washed thrice in 1X TBST prior to a onehour incubation with secondary antibody. Membranes were incubated with antiLC3A/LC3B polyclonal antibody (Invitrogen, Thermo Fisher Scientific, USA) and
horseradish peroxidase- (HRP-) conjugated goat anti-rabbit IgG secondary antibody
(Invitrogen, Thermo Fisher Scientific, USA) for LC3-I and LC3-II detection. HRPconjugated anti-β-actin monoclonal antibody (Invitrogen, Thermo Fisher Scientific,
USA) was incubated with the membranes for detection of β-actin.

2.19 Protein Detection and ECL Imaging
Protein

abundance

was

detected

on

PVDF

membranes

using

enhanced

chemiluminescence (ECL). Immobilon Forte Western HRP Substrate (Millipore Sigma,
Burlington, MA, USA) was used to incubate the membrane for ECL detection of target
protein. The ChemiDoc Imaging System and Image Lab Touch Software (Bio-Rad, USA)
were used to capture images of the membrane using the chemiluminescence settings.

2.20 Volumetric Analysis
Images of the western blot from ECL imaging were processed with volumetric analysis
using ImageLab software (Bio-Rad, USA) to quantify for protein abundance.
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2.21 Statistical Analysis
Statistical analysis for all experiments were performed on Prism 8 (GraphPad, USA).
One-way ANOVA and if significant, Tukey’s HSD post-hoc tests were performed to
compare means between each treatment groups. Experiments were performed with a
minimum of three biological replicates. P values less than 0.05 were considered
statistically significant.
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Chapter 3

3

Results

3.1 Effects of PA and OA on Preimplantation Development
Previously, it was established in our lab, that exposure to 100 µM of PA significantly
reduced blastocyst development whilst co-culture with 250 µM of OA resulted in similar
blastocyst formation as control levels (Yousif et al. 2020). My first experiment
investigated the effects of 100 µM PA and 250 µM OA, individually and in combination,
throughout mouse preimplantation embryo development. Representative images of 2-cell
staged mouse embryos after 18, 24, 30, 40, and 48 hours of PA and OA exposure,
individually and in combination, are shown in Figure 7.
Developmental progression was analyzed for each treatment group after 18, 24, 30, 40,
and 48 hours of NEFA exposure beginning at the 2-cell stage. No significant differences
were found between treatment groups for the developmental progression of embryos at
the 4-cell, 8-cell, and morula stage after 18 and 24 hours of NEFA exposure (Figure 8, P
> 0.05, Tukey’s multiple comparisons test). No blastocyst formation was observed at
these two timepoints. After 30 hours of NEFA exposure, the development of mouse
embryos to the 4-cell and 8-cell stage embryos were similar between each treatment
group (Figure 8, P > 0.05, Tukey’s multiple comparisons test). Development to the
morula stage after 30 hours of PA+OA co-culture was significantly lower than control
group (Figure 8, P < 0.05, Tukey’s multiple comparisons test); while morula
development was similar in PA- and OA-alone groups. No blastocyst formation was
observed at this the 30-hour time point as well in any treatment group including controls.
At the 40-hour time point, no significant differences were observed across treatment
groups for all cell stages, including the morula stage (Figure 8, P > 0.05, Tukey’s
multiple comparisons test). However, after 48 hours of incubation, exposure to PA alone
resulted in a significantly higher proportion of 8-cell stage embryos than other treatment
groups (Figure 8, P < 0.001, Tukey’s multiple comparisons test). Development to the
blastocyst stage in the PA-alone group was correspondingly significantly reduced
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(Figure 8, P < 0.01, Tukey’s multiple comparisons test). However, blastocyst
development was similar in the PA+OA combination group to the control; OA-only
group also showed no significant differences (Figure 8, P > 0.05, Tukey’s multiple
comparisons test).
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Figure 7. Representative images of embryos cultured in NEFA treatments
Representative images of mouse preimplantation embryos treated with 100 µM PA, 250
µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium alone (control), beginning at
the 2-cell stage for 18, 24, 30, 40, and 48 hours. Scale bar = 100 µm.
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Figure 8. Developmental stage progression of embryos after NEFA treatments
Developmental stage progression (+ SEM) of mouse preimplantation embryos treated
with 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium alone
(control) beginning at the 2-cell stage for 18, 24, 30, 40, and 48 hours. N > 4, one-way
ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated by *p <
0.05, **p < 0.01, and ***p < 0.001.
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3.2 Autophagic profile throughout preimplantation
development
The first primary objective aimed to assess autophagy onset throughout mouse
preimplantation embryo development. To do so, I first characterized the expression of
autophagy markers at the transcript and protein levels for all cell stages of mouse
preimplantation development. The relative transcript abundance of Bcln1, ATG3, ATG5,
and LC3 were evaluated. Bcln1 transcript abundance, normalized to internal standard
luciferase mRNA levels, was significantly decreased at the first cleavage then maintained
low levels until the morula stage (Figure 9A, P < 0.05, Tukey’s multiple comparisons
test). Relative Bcln1 transcript levels returned to zygote levels at the blastocyst stage
(Figure 9A). In contrast, relative ATG3 transcript levels, normalized to luciferase mRNA
levels, were not significantly different across all preimplantation development stages
(Figure 9B, P = 0.1266, one-way ANOVA). Interestingly, relative ATG5 transcript
levels, normalized to luciferase mRNA, significantly dropped from the zygote stage by
more than 5-fold after first cleavage and stayed at a low relative level throughout
preimplantation development (Figure 9C, P < 0.05, Tukey’s multiple comparisons test).
Lastly, relative LC3 transcript levels, normalized to luciferase mRNA, significantly
increased from the zygote stage by approximately 15-fold at the blastocyst stage (Figure
9D, P < 0.05, Tukey’s multiple comparisons test).
The analysis of LC3-II puncta, observed via fluorescence microscopy, is regarded as a
specific marker for autophagosomes number (Mizushima et al. 2010, Figure 10).
Relative levels of LC3-II puncta were evaluated at all stages of mouse preimplantation
development. LC3-II puncta count per cell significantly decreased after the 2-cell stage,
to represent a 100-fold decrease by the blastocyst stage (Figure 10A, P < 0.05, Tukey’s
multiple comparisons test). Representative images of LC3-II puncta at all preimplantation
developmental stages are shown in Figure 10B.
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Figure 9. Autophagic marker transcript abundance in preimplantation development
Relative autophagic marker transcript levels (+ SEM) of preimplantation mouse embryos
at 1-cell, 2-cell, 4-cell, 8-cell, morula, and blastocyst stage. N > 3, one-way ANOVA
with Tukey’s HSD post-hoc test. Significant differences are indicated by *, p < 0.05.
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Figure 10. Autophagy marker LC3-II in preimplantation embryo development
Relative percent LC3-II aggregate puncta formation per cell (+ SEM) of preimplantation
mouse embryos at 2-cell, 4-cell, 8-cell, morula, and blastocyst stage (A). N > 3, one-way
ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated by ****p
< 0.0001 and *p < 0.05. Representative images of LC3-II aggregate puncta formation at
each preimplantation stage (B).
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3.3 Effects of PA and OA on overall autophagy
As mouse preimplantation development is negatively affected by PA treatment and
rescued by PA and OA combination treatment, it is important to investigate whether
exposures to PA and OA alters overall autophagy induction during this developmental
period. Thus, I next characterized the pattern of relative autophagic marker transcript
levels after 48 hours of NEFA exposure. The autophagic markers selected for
investigation included Bcln1, ATG3, ATG5, and LC3. RT-qPCR transcript analysis
revealed no significant differences in relative transcript abundance between control, 100
µM PA, 250 µM OA, and PA+OA co-treatment groups for all four autophagic markers
(Figure 11A, P = 0.9680 (Bcln1); Figure 11B, P = 0.9057 (ATG3); Figure 11C, P =
0.7418 (ATG5); Figure 11D, P = 0.9548 (LC3), one-way ANOVA).
I then investigated whether autophagy is affected by NEFA exposure at the protein level,
as reflected by the level of autophagosome detection via the characterization of LC3-II
puncta levels using confocal microscopy. LC3-II puncta determination was applied to
mouse preimplantation embryos following 18, 24, 30, 40, and 48 hours NEFA treatments.
At both 18 and 24 hours NEFA treatment, no significant difference in LC3-II puncta per
cell were observed in the PA and OA group, alone and in combination, from that
observed in the control group (Figure 12A, Figure 13A, P > 0.05, Tukey’s multiple
comparisons test).
Significant variations in LC3-II puncta count per cell were first observed after 30 hours
of NEFA exposure. Mouse embryos at the 2-cell stage were treated with 100 µM of PA
for 30 hours displayed a significant increase in LC3-II puncta count per cell compared to
treatment with 250 µM of OA for the same time interval (Figure 14A, P < 0.05, Tukey’s
multiple comparisons test). Likewise, treatment of 2-cell embryos with the PA+OA
combination treatment for 30 hours also significantly increased LC3-II puncta count per
cell compared to OA-alone treatment (Figure 14A, P < 0.01, Tukey’s multiple
comparisons test) as well as control (Figure 14A, P < 0.05, Tukey’s multiple
comparisons test). No significant differences were observed between PA-alone and
PA+OA combination group (Figure 14A, P = 0.9560, Tukey’s multiple comparisons
test).
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After 40 hours of NEFA treatment, variation in LC3-II puncta per cell counts across
different treatment groups were enhanced. Two-cell mouse embryos treated with 100 µM
of PA for 40 hours displayed a significant increase in LC3-II puncta per cell by more than
two-fold compared to the control (Figure 15A, P < 0.0001, Tukey’s multiple
comparisons test). The same relative increase in LC3-II puncta per cell was also observed
in 2-cell mouse embryos treated with the PA+OA co-treatment for 40 hours (Figure 15A,
P < 0.001). Treatment with 250 µM of OA alone resulted in LC3-II puncta count per cell
levels that were not significantly different than the control group (Figure 15A, P >
0.9999, Tukey’s multiple comparisons test). Comparison of the PA-alone treatment and
PA+OA combination treatment to the OA-alone treatment resulted in a significant
increase in LC3-II puncta count per cell between groups (Figure 15A, P < 0.001,
Tukey’s multiple comparisons test).
I also assessed the effects of 48 hours of NEFA treatment on LC3-II puncta count per cell
across all treatment groups. Consistent with other time intervals, treatment of 2-cell
mouse embryos with 100 µM of PA for 48 hours significantly increased LC3-II puncta
per cell compared to treatment with 250 µM of OA alone (Figure 16A, P < 0.05, Tukey’s
multiple comparisons test). However, in contrast to previous time points, 2-cell mouse
embryo treatment with PA+OA in combination for 48 hours resulted in no significant
difference in LC3-II puncta count per cell between this group and the OA-alone group
(Figure 16A, P = 0.9945, Tukey’s multiple comparisons test). Interestingly, PA+OA cotreatment for 48 hours resulted in a significant reduction in LC3-II puncta count per cell
than that observed for the PA-only treatment, which was a unique outcome observed only
in this time point (Figure 16A, P < 0.05, Tukey’s multiple comparisons test).
Representative images of LC3-II puncta per cell of 2-cell mouse embryos following
treatment with NEFAs for 18, 24, 30, 40, and 48 are shown (Figure 12B, 13B, 14B, 15B,
16B).
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Figure 11. Autophagic marker transcript abundance in NEFA-treated embryos
Relative autophagic marker transcript levels (+ SEM) of preimplantation mouse embryos
treated with 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa
medium alone (control) for 48 hours. N=3, one-way ANOVA. Relative transcript levels
for all 4 selected targets did not vary significantly across treatment from controls.
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Figure 12. Autophagy marker LC3-II in NEFA-treated embryos after 18 hrs. of
NEFA treatment
Relative percent aggregate puncta formation of LC3-II per cell (+ SEM) of 2-cell mouse
embryos in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium
alone (control) for 18 hours (A). Only embryos past the 4-cell stage are included. N=3,
two-way ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated
by *, p < 0.05. Representative images of LC3-II aggregate puncta formation after NEFA
exposure (B). Scale bar = 100 µm.
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Figure 13. Autophagy marker LC3-II in NEFA-treated embryos after 24 hrs. of
NEFA treatment
Relative percent aggregate puncta formation of LC3-II per cell (+ SEM) of 2-cell mouse
embryos in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium
alone (control) for 24 hours (A). Only embryos past the 4-cell stage are included. N=3,
two-way ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated
by *, p < 0.05. Representative images of LC3-II aggregate puncta formation after NEFA
exposure (B). Scale bar = 100 µm.
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Figure 14. Autophagy marker LC3-II in NEFA-treated embryos after 30 hrs. of
NEFA treatment
Relative percent aggregate puncta formation of LC3-II per cell (+ SEM) of 2-cell mouse
embryos in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium
alone (control) for 30 hours (A). Only embryos past the 4-cell stage are included. N=3,
two-way ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated
by *, p < 0.05. Representative images of LC3-II aggregate puncta formation after NEFA
exposure (B). Scale bar = 100 µm.
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Figure 15. Autophagy marker LC3-II in NEFA-treated embryos after 40 hrs. of
NEFA treatment
Relative percent aggregate puncta formation of LC3-II per cell (+ SEM) of 2-cell mouse
embryos in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium
alone (control) for 40 hours (A). Only embryos past the 8-cell stage are included. N=3,
two-way ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated
by *, p < 0.05. Representative images of LC3-II aggregate puncta formation after NEFA
exposure (B). Scale bar = 100 µm.
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Figure 16. Autophagy marker LC3-II in NEFA-treated embryos after 48 hrs. of
NEFA treatment
Relative percent aggregate puncta formation of LC3-II per cell (+ SEM) of 2-cell mouse
embryos in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium
alone (control) for 48 hours (A). Only embryos of the blastocyst stage are included. N=3,
two-way ANOVA with Tukey’s HSD post-hoc test. Significant differences are indicated
by *, p < 0.05. Representative images of LC3-II aggregate puncta formation after NEFA
exposure (B). Scale bar = 100 µm.
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3.4 Effects of PA and OA on autophagosome formation
Since autophagy is comprised of multiple steps (figure 2 to 5), my next objective was to
assess autophagosome formation in NEFA-treated mouse embryos, employing an
autophagy inhibitor, chloroquine (CQ). CQ inhibits autophagy by increasing the pH of
lysosomes and thus preventing autophagosome-lysosome fusion (Mauthe et al. 2018). My
preliminary data (Appendix A and B) determined that treatment of mouse embryos with
CQ, at 75 µM for two hours, allows for the detection of significant differences in LC3-II
employing both western blot (Supplementary Figure 3) and LC3-II puncta cell counts
by immunofluorescence (Supplementary Figure 4). This experimental protocol and
design resulted in no observable changes in morphology between CQ-treated blastocysts
and non-treated controls (Supplementary Figure 2). My preliminary data (Appendix C)
confirms that CQ treatment inhibits autophagy in mouse preimplantation embryos.
Mouse embryos at the 2-cell stage were treated with NEFAs for 40 hours with a 75 µM
CQ treatment applied during the last two hours of the total treatment period. The
immunofluorescence signal of LC3-II puncta aggregates per cell was analyzed for each
treatment group. In all treatment groups with CQ, no significant difference in the levels
of LC3-II puncta fluorescence per cell were observed compared to its corresponding
treatment group without CQ control (Figure 17, P > 0.05, Tukey’s multiple comparisons
test). The PA+CQ group, displayed a significant increase in fluorescence signal of LC3-II
puncta aggregates per cell than all other non-PA treatment groups (Figure 17, P < 0.05,
Tukey’s multiple comparisons test). Specifically, treatment of PA+CQ resulted in
approximately a 2-fold increase in fluorescence signal of that observed for the CON+CQ
group (Figure 17, P < 0.01, Tukey’s multiple comparisons test) as well as OA+CQ and
PAOA+CQ groups (Figure 17, P < 0.05, Tukey’s multiple comparisons test). No
significant differences in fluorescence intensity of LC3-II puncta aggregate per cell were
observed between CON+CQ, OA+CQ, and PAOA+CQ groups (Figure 17, P > 0.9999,
Tukey’s multiple comparisons test). Figure 18 displays representative images of LC3-II
aggregate puncta formation after NEFA +/- CQ treatments for 40 hours.
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Figure 17. Autophagic flux of embryos after NEFA+/- CQ treatment for 40 hours.
Fluorescence signal of LC3-II puncta per cell after 40 hours of treatment with 100 µM
PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa medium alone (control), and
75 µM of chloroquine exposure for the last 2 hours (+ SEM). Only embryos of 8-cell
stage and up were included. N=3, one-way ANOVA and Tukey’s HSD post-hoc test.
Significant differences are indicated by *p < 0.05 and **p < 0.01.
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3.5 Effects of PA and OA on autophagosome maturation
and degradation
To investigate effects to additional key steps in the autophagic process I next assessed
autophagosome-lysosome interactions in NEFA-treated mouse embryos. Mouse embryos
at the 2-cell stage were exposed to NEFA for 40 hours then the co-localization of LC3-II
puncta and lysosomes were analyzed.
Assessment of the average number of LC3-II-lysosome co-localized puncta per cell
revealed that mouse embryos exposed to 250 µM of OA resulted in an approximately 3fold significant increase of co-localized puncta than embryos treated with 100 µM of PA
alone (Figure 19A, P < 0.05, Tukey’s multiple comparisons test). Representative images
of LC3-II-lysosome co-localized puncta after NEFA treatment is shown in figure 19B.
When the total LC3-II puncta count per cell were measured, the proportion of LC3-IIlysosome co-localized puncta per cell out of total LC3-II puncta per cell across each
treatment group were also measured. This analysis demonstrated that treatment with 250
µM of OA resulted in a significantly higher proportion of autolysosome per cell than that
observed in embryos treated with 100 µM of PA alone (Figure 20, P < 0.05, Tukey’s
multiple comparisons test).
Finally, an experiment was carried out to investigate the effects of PA and OA treatment
on lysosomal activity. Mouse embryos at the 2-cell stage were exposed to NEFA for 40
hours then the fluorescence signal of LysoTracker Red, representing lysosomal activity,
was analyzed. Comparison of the fluorescence signal across each treatment group
revealed that after treatment with 100 µM of PA for 40 hours, LysoTracker Red
fluorescence intensity was significantly lower compared to all other NEFA groups
(Figure 21A, P < 0.01, Tukey’s multiple comparisons test). Meanwhile, LysoTracker
Red fluorescence intensity after 40 hours of treatment with 250 µM of OA alone or
PA+OA co-treatment resulted in no significant differences from that observed in the
control group (Figure 21A, P > 0.05, Tukey’s multiple comparisons test). Representative
images of LysoTracker Red fluorescence signal after NEFA exposure for 40 hours are
shown in figure 21B.
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Figure 19. Autophagosome-lysosome co-localization in embryos after 40 hrs. of
NEFA treatments
Average number of LC3-II-lysosome co-localized puncta per cell (+SEM) after treatment
for 40 hours with 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa
medium alone (control) (A). Only embryos of 8-cell stage and up were included. N=3,
one-way ANOVA and Tukey’s HSD post-hoc test. Significant differences indicated by *,
p < 0.05. Representative images of LC3-II-lysosome co-localized puncta after NEFA
exposure (B). Arrows indicate for LC3-II-lysosome co-localized puncta. Scale bar = 100
µm.
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Figure 20. Autolysosome in embryos after 40 hrs. of NEFA treatments
Relative proportion of LC3-II-lysosome co-localized puncta per cell to total LC3-II
puncta per cell (+SEM) following 40 hours of treatment with 100 µM PA, 250 µM OA,
100 µM PA and 250 µM OA, or KSOMaa medium alone (control). Only embryos of 8cell stage and up were included. N=3, one-way ANOVA with Tukey’s HSD post-hoc
test. Significant differences are indicated by *p < 0.05.
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Figure 21. LysoTracker signal in embryos after NEFA treatments for 40 hrs.
Relative percentage of LysoTracker fluorescence signal (+SEM) under 40 hours
treatment with 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or KSOMaa
medium alone (control) (A). N=4, one-way ANOVA with Tukey’s HSD post-hoc test.
Significant differences are indicated by *p < 0.05. Representative images of 2-cell mouse
embryos in NEFA treatments for 40 hours (B). Scale bars = 100 µm.
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Chapter 4

4

Discussion

A developing preimplantation embryo is highly vulnerable to the surrounding
environment provided by the follicular and reproductive tract fluid(s). Profiling the
follicular fluids of women undergoing ART identified the presence of NEFAs including
PA and OA and determined that fatty acids are especially elevated in those women with a
high BMI index (Valckx et al 2014). The effects of PA and OA treatments on a variety of
cell types are the subject of intense investigation but very few have explored their effects
on preimplantation embryos. Recently, our lab reported developmental impacts brought
upon by PA and OA exposure during mouse preimplantation development. Our study
uncovered several of the possible underlying mechanisms that contribute to the reduced
developmental competency exhibited by PA treated embryos including the activation of
ER stress pathway(s) (Yousif et al. 2020). ER stress activation initiates several cell
survival mechanisms, with one being autophagy (Ogata et al. 2006). Autophagy is an
evolutionarily conserved mechanism in eukaryotic organisms that acts as a “last resort” to
maintain cellular homeostasis before initiating apoptosis (Lee et al. 2015). Despite its
essential role in cell survival, the importance of autophagy in preimplantation
development was only first indicated by Tsukamoto et al. (2008). This study
demonstrated that autophagy activation, especially after fertilization, is required for
proper mouse preimplantation development (Tsukamoto et al. 2008). However, the
potential role that autophagy may contribute during preimplantation development
following NEFA treatment was not considered. Thus, my thesis aimed to characterize and
model the autophagic underpinnings impacted by obesity-induced hyperlipidemia during
early mouse embryo development in vitro. Overall, it was hypothesized that NEFAinduced lipotoxicity would dysregulate autophagic mechanisms in mouse preimplantation
development. Specifically, PA would disrupt autophagosome formation while the
addition of OA would negate lipotoxic effects and enhance overall developmental
success. To test this hypothesis, three objectives were investigated to first, assess
autophagy in NEFA-treated mouse embryos throughout preimplantation development;
second, to assess autophagosome formation in NEFA-treated embryos; and third, to
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assess autophagosome-lysosome interactions in NEFA-treated mouse preimplantation
embryos.

4.1 NEFA effects on mouse preimplantation development
To characterize the NEFA effects on preimplantation embryos, mouse preimplantation
embryos were treated with 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA, or
KSOMaa medium alone (control) beginning at the 2-cell stage for 18, 24, 30, 40, and 48
hours. This study presents outcomes from the first NEFA treatment time-course study
that has characterized NEFA treatment effects on development of mouse early embryos.
Developmental progression of treated 2-cell stage embryos was not affected by NEFA
treatment during the first 24 hours of treatment. However, as the NEFA treatment time
increases, important differential treatment effects on preimplantation development begin
to appear. Consistent with our previous findings (Yousif et al. 2020), treatment of 2-cell
stage mouse embryos with 100 µM PA for 48 hours resulted in a significant decrease in
blastocyst development as embryos were arrested at the 8-cell stage. As well, the
treatment of mouse embryos beginning at the 2-cell stage with 250 µM OA resulted in no
beneficial effect nor impairment of preimplantation development, and this also consistent
with our previous findings (Yousif et al. 2020). Similar results from PA and OA
treatments were also reported in studies applied to bovine early embryos which suggests
that both embryo species may employ similar adaptive mechanisms to adjust to changing
NEFA level environments. Leroy et al. (2005) reported the addition of PA in oocyte
maturation medium reduced cleavage rate and blastocyst yield of bovine embryos in
vitro; while OA had no effects on developmental capacity compared to controls.
To our surprise, the treatment of 100 µM PA and 250 µM OA in combination resulted in
a reduction in morula stage embryos at the 30-hour time point compared to the control
group. This is the first report that a PA and OA combination treatment can slow
preimplantation developmental progression. Although PA and OA combination treatment
displayed a slower progression through the early cleavage stages, a “catch-up growth”
effect occurred at the end of preimplantation development that resulted in no differences
in blastocyst frequencies between the PA and OA combination treatment and untreated
controls. I would propose that the slowed progression and catch-up growth effect could
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potentially be due to differential uptake rates for each individual fatty acids at varying
embryo cell stages. Wang and Tsujii (1999) reported significant differences in
incorporation rate of PA and OA at different stages of preimplantation mouse
development. The incorporation of PA into embryo lipids steadily increases throughout
mouse preimplantation development, whereas OA is mostly incorporated into
triacylglycerol (TAG) at an exponential rate at the morula and blastocyst stage (Wang
and Tsujii 1999). Thus, PA uptake exceeds OA uptake at all preimplantation stages
except at the blastocyst stage (Wang and Tsujii 1999). Early-stage preferential PA uptake
and its possible conversion to diacylglycerol (DAG) and likely ceramide (Listenberger et
al. 2003) could explain the detrimental effect of PA treatment resulting in developmental
arrest between the 4- to 8-cell stages. The addition of OA in the combination treatment,
despite having a delayed initial uptake during early cleavage stages, undergoes an
exponential increase in uptake to more than 1.5-fold of PA uptake at the blastocyst stage
(Wang and Tsujii 1999). As studies investigating OA treatment effects on cells generally
conclude that OA is beneficial for regulating cell metabolism and inflammation (Fayezi
et al. 2018), the surge of OA uptake at the later preimplantation stages could promote this
“catch-up growth” that rescues blastocyst development levels in the PA and OA
combined treatments. Additionally, the cellular conversion of OA to oxidative
metabolism energy intermediates and phospholipids as demonstrated by Wang and Tsujii
(1999) suggests OA treatment alone or in combination with PA can assist in regulating
the required energy and cell membrane structural demands for accelerated growth to the
blastocyst stage. My results also suggest that this process is well underway by 30 hour of
combined treatment and is certainly well in place by 40 hours of co-treatment as
developmental stage differences between the untreated control and PA and OA cotreatment were no longer observed at the 40-hour time point or beyond. In total, my
results support that OA exerts an ability to offset PA treatment-induced developmental
impairments. Uniquely my study has defined a developmental window between 30 to 40
hrs of treatment where OA fully engages in providing this beneficial outcome to the early
embryo.
The dosage of PA and OA used in the experimental design was established based on
Yousif et al. (2020). The dosage of PA and OA employed approximates the serum levels
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of NEFAs found in individuals undergoing IVF treatments, whom BMI index averages at
25 (Jungheim et al. 2011). As reported by Jungheim et al. (2011), the mean serum PA
concentration was 150 µM and mean serum OA concentration was 220 µM. Jungheim et
al. (2011) also reported a three-fold reduction in NEFA concentrations in follicular fluids
compared to serum levels at 56 µM for PA and 64 µM for OA. Another study by Valckx
et al. (2014) reported total NEFA concentration of follicular fluids of obese individuals
with BMI index over 35 averages at 315.5 µM; levels of PA and OA in the follicular
fluids was at 70.3 µM and 102.5 µM, respectively. It is important to note though, PA and
OA exist in different forms in the follicular fluid, including triglycerides, cholesterol
esters, and phospholipids in addition to non-esterified forms. PA and OA are both the
most abundant fatty acids existing in all these forms regardless (Valckx et al. 2014). My
studies were of course represented an in vitro model of PA and OA exposure on
preimplantation development. They provide important outcomes that represent
foundational discoveries that are required to understand the differential effects of PA and
OA treatments on mouse preimplantation development. Thus, my outcomes have direct
application to improving in vitro culture environments. OA treatment may become an
important additional embryo culture medium constituent as it could improve blastocyst
development of embryos that were maternally exposed to high fatty acid levels.

4.2 Autophagy throughout preimplantation development
Tsukamoto et al. (2008) observed that autophagy is induced after fertilization and that
knockout of the autophagy-related gene 5 (ATG5) gene expression in early mouse
embryos results in developmental arrest at the 4- to 8-cell stage, and even embryo
lethality. ATG5 is essential for autophagosome membrane elongation and formation
(Melia et al. 2020). Although autophagy is clearly important and necessary for normal
preimplantation development to occur, the temporal pattern of key transcripts encoding
key autophagic pathway constituents throughout mouse preimplantation development
were not well known. Thus, to assess relative transcript level of autophagy pathway
markers throughout preimplantation development, mouse embryos were cultured in
KSOMaa medium and collected at 1-cell, 2-cell, 4-cell, 8-cell, morula, and blastocyst
stages.
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RT-qPCR analysis of mRNA transcript levels of autophagic markers Becn1, Atg3, Atg5,
and Map1lc3b were conducted. Beclin-1 is an essential component of the PI3K complex
that initiates for phagophore nucleation (Noda et al. 2010). It also plays a regulatory role
in apoptosis by freeing Bcl-2 to inhibit pro-apoptotic protein BAX (Hill et al. 2019). The
relative mRNA transcript level of Beclin-1 in preimplantation mouse embryos
significantly declined after the 1-cell stage and then gradually restored the 1-cell level
again by the blastocyst stage. This pattern of relative mRNA levels throughout mouse
preimplantation development is very common for many other key developmental
transcripts (Li et al. 2013). It reflects the well-known loss and degradation of maternal
transcripts that occurs in fertilized 1-cell embryos and is largely completed by the 2-cell
stage, followed by embryonic/zygotic genome activation (ZGA) and a stage specific
increase in relative mRNA transcript level up to the blastocyst stage. A study by Lee et
al. (2011) reported similar mRNA expression patterns for of Beclin-1 in mouse
preimplantation embryos in which transcript levels gradually decreased from the zygote
to the blastocyst stage; but no recovery of mRNA level was observed at the blastocyst
stage (Lee et al. 2011). A study of Beclin-1 mRNA transcript abundance in porcine
embryos also observed a gradual decrease as embryos progressed through
preimplantation stages with no restoration of Beclin-1 mRNA levels (Xu et al. 2012).
Thus, it is well understood that Beclin-1 mRNA expression during early preimplantation
stages is of maternal genome origin. However, my discovery of a restoration of Beclin-1
mRNA transcript levels at the blastocyst stage is novel and one that suggests the
embryonic genome is capable of transcribing Beclin-1 during preimplantation
development. This difference between studies could simply be due to my investigation
using later stage blastocysts and hatching blastocysts (E4.5) which are more advanced
that those employed in other studies. An assessment of autophagy activity in rat embryos
conducted by Ekizceli et al. (2017) found that autophagy increases in both trophoblast
and inner cell mass during embryo implantation. Thus, the relative increase in Beclin-1
mRNAs at the blastocyst stage that I detected underlie the elevation of autophagy in the
late blastocysts as they prepare for implantation. Further studies are required to determine
if this possibility has merit.
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ATG3 is an essential activator protein that attaches a phosphatidylethanolamine (PE)
onto LC3-I to become activated LC3-II. This activation is required for autophagosome
formation (Ravanan et al. 2017). The relative ATG3 mRNA transcript levels in
preimplantation mouse embryos remained identical across all preimplantation stages.
Although no significant differences were observed in relative ATG3 transcript levels
between stages, it was readily detected in all embryo stages. This suggests the possibility
that ATG3 mRNA has a relatively short half-life throughout mouse preimplantation
development, and that its steady production throughout all stages is a functional
autophagic pathway requirement for development and its consistent LC3-II activation
pattern.
ATG5 orchestrates autophagosome formation by recruiting membrane-bound proteins to
deliver cargo contents for degradation. My results showed that relative transcript
abundance of ATG5 mRNA drops significantly after the 1-cell zygote stage. In
agreement with these findings, Lee et al. (2011) reported a significant drop in ATG5
mRNA expression after the 1-cell stage in mouse embryos. Similarly, a study by Xu et al.
(2012) also reported a significant decrease in ATG5 mRNA transcript after the 1-cell
stage in porcine embryos. This relative transcript abundance pattern across
preimplantation stages is highly suggestive of ATG5 transcripts being primarily of
oogenetic genome origin. The gradual decrease observed post-1-cell stage likely arises
due to maternal transcript turnover as early embryos progress through each subsequent
developmental stage. Interestingly, normal levels of autophagy were observed in ATG5
knock-out 2-cell embryos derived from heterozygous ATG5 mice (Tsukamoto et al.
2008), which confirms that ATG5 transcripts are derived from the maternal genome and
that while autophagy is necessary during preimplantation development, minimal levels of
ATG5 are required to support autophagy during preimplantation development.
Activated LC3, LC3-II protein is critical for autophagosome formation as LC3-II acts as
a binding site for cargo contents bound for degradation (Ravanan et al. 2017). LC3 is
produced as a precursor prior to activation to LC3-I and -II (Ravanan et al. 2017). I
observed that relative LC3 mRNA transcript abundance maintains similar levels
throughout the early cleavage stages and then gradually increases as the embryos
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progress to the blastocyst stage. Previously, the study by Lee et al. (2011) reported a
gradual decrease of mRNA transcript of LC3 throughout mouse preimplantation stages
and the study by Xu et al. (2012) also reported the same pattern in porcine embryos.
Interestingly, Noguchi et al. (2020) reported that in vitro and in vivo produced bovine
blastocysts displayed significant differences in the relative mRNA levels of PI3K-AktmTOR pathway constituents that support autophagy pathway activation. Since my studies
were confined to stages resulting from the placement of 2-cell stage mouse embryos in
culture up to the blastocyst stage, it is possible the increase in LC3 transcript I observed
by the blastocyst stage, is a result of the prolonged culture period that my embryos were
exposed to. Further experiments are required to determine if in vitro vs in vivo stage
differences exist for these autophagy pathway constituent mRNAs in mouse
preimplantation embryos.
LC3-II is a widely accepted marker for autophagy as it is present on the outer membranes
of autophagosomes. Mizushima et al. (2010) described multiple assays for measuring
autophagy and highlighted that the use of fluorescence microscopy to assess LC3-II
puncta representing autophagosomes as an accessible and powerful method. In the
current study, the relative percentage of LC3 puncta per cell significantly decreased from
the 2-cell stage to the blastocyst stage. Lee et al. (2011) supported this finding as LC3 is
observed in mouse preimplantation embryos at all cell stages via immunofluorescence
staining, though the authors did not make quantitative comparisons between embryo
stages. Interestingly, the significant decrease in LC3-II puncta counts per cell throughout
preimplantation development was opposite to the increase LC3 relative mRNA transcript
levels observed. This is partially explained by the way in which both methods were
applied. While LC3-II puncta per cell decreased as development advanced, embryonic
cell number dramatically increased during preimplantation development, so that total
LC3-II puncta per embryo also increased as development proceeded. However, we were
primarily interested in providing a measurement of autophagic activity per stage and this
typically is measured by determining LC3-II puncta per cell. Thus, while puncta per cell
decreased during mouse preimplantation development, suggesting a per cell decrease in
autophagy, from a whole embryo perspective it actually increased per embryo as
development proceeded, which conforms nicely with the relative increase in LC3 mRNA
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observed by the blastocyst stage. Importantly, the activation of LC3 into LC3-II may be
limited by the availability of ATG3 (Agrotis et al. 2019). ATG3 transcript levels
remained relatively stable across all preimplantation stages. Activation of LC3 may
therefore be limited by the turnover of ATG3 protein and the demand to initiate
autophagy to maintain cell homeostasis. Another important aspect worth noting is that
LC3 mRNA could have a short half-life and thus LC3 activation may be tightly
regulated, resulting in the net low levels of LC3-II puncta per cell observed at the later
stages of preimplantation development. My study and results are the first report
demonstrating that autophagy activation per cell significantly decreases throughout
preimplantation development.

4.3 NEFA effects on preimplantation embryo autophagy
Previous sections reported negative impacts of PA treatment on preimplantation
development in mouse embryos and those PA-induced effects could be negated by OA
treatments. As autophagy plays a role throughout development to maintain cell
homeostasis, the primary objective of this thesis was to assess NEFA effects on
autophagy in preimplantation embryos. Relative mRNA transcript analysis of autophagic
markers (Becn1, Atg3, Atg5, and Map1lc3b) did not result in the detection of any
significant differences at the transcript level following 48 hours of NEFA treatment,
which suggests that NEFA treatment did not affect the relative transcriptional patterns
and half-lives of the selected autophagic markers. In support of this outcome, studies
applied to C2C12 mouse myoblast cells, observed no change in LC3 mRNA transcript
levels after 48 hours of co-treatment of PA and OA at 250 µM each (Bollinger et al.
2018). Furthermore, studies applied to mouse hepatic cells, observed no change in ATG5
mRNA levels after prolonged high-fat diet (Okada et al. 2017). NEFA exposure appears
to have limited impact on autophagic pathway constituent at the mRNA level for various
cell types, though more evidence is required to confirm our findings.
My thesis also presented, for the first time, the temporal pattern of protein expression of
LC3-II after exposure to NEFA treatments throughout mouse preimplantation
development. No significant changes in relative percentage of LC3-II puncta count per
cell was observed between groups after 18 and 24 hours of NEFA treatment beginning at

79

the 2-cell stage. Wang and Tsujii (1999) reported significant differences in incorporation
rate of PA and OA at different preimplantation stages in mouse embryos – the uptake of
PA exceeds OA uptake specifically at the earlier stages. Though, the treatment of PA did
not result in significant changes in autophagy during the first 24 hours of preimplantation
development. These results certainly suggest that the effects of PA and OA treatment at
the doses employed in this study require longer than 24 hrs of exposure to affect
autophagy activation. The temporal pattern of autophagy in nerve cells after stressors like
spinal cord injury summarized that the activation of autophagy is delayed for hours to
even days after the injury, regardless of the types of nerve cells (Zhou et al. 2017).
Although the level of autophagy is likely dependent on the severity of the stressor, nonimmediate activation of autophagic activity was a common element across several
divergent cell systems and tissues (Zhou et al. 2017).
Importantly, 2-cell mouse embryos exposed to PA-only and PA and OA co-treatment for
30 hours did show a significant increase in percentage of LC3-II puncta per cell than OAalone treatment. This outcome appears to define a treatment period required using the
NEFA doses employed in this study to activate autophagy in an effort re-establish
embryo homeostasis. The induction of autophagy, as reflected by LC3-II puncta count,
likely occurred between 24 and 30 hours of PA exposure. I speculate that PA treatment
disrupted ER homeostasis and induced ER stress, which led to the initiation of UPR as
well as the activation of autophagy to maintain homeostasis. Yousif et al. (2020) reported
that PA treatment induces ER stress pathways constituents in preimplantation mouse
embryos. Notably, the treatment of 2-cell mouse embryos with PA increased x-box
binding protein 1 (XBP1) mRNA splicing in the inositol-requiring protein 1α (IRE1α)
arm of the ER stress pathway (Yousif et al. 2020). Such mRNA splicing of the XBP1
creates the active XBP1 protein that acts as a nuclear transcription factor to induce gene
expression of autophagy-related proteins like Beclin-1 in endothelial cells (Margariti et
al. 2013). Additionally, autophagy can also be initiated by AMPK activity via direct
activation of ULK1 (Kim et al. 2011). The elevated transcription of autophagy-related
genes by PA-induced effects potentially contributes to the elevated presence of
autophagosomes (as reflected by the elevated level of LC3-II puncta count per cell) in the
PA group after 30 hours of treatment. In contrast, OA treatment had no effect on the
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percentage LC3-II puncta per cell than control. The presence of LC3-II puncta in the OA
treatment group immunofluorescence images likely represents basal levels of autophagy.
The same overall outcome was observed after 40 hours of NEFA exposure, but to a
greater extent. Exposure of 2-cell mouse embryos to PA-only and PA and OA cotreatment for 40 hours resulted in a significantly greater percentage of LC3-II puncta per
cell than control and OA groups. The OA treatment group remained the same as control
in terms of percentage LC3-II puncta per cell after 40 hours of treatment.
However, after exposure to 48 hours of NEFA treatments, the percentage of LC3-II
puncta per cell dropped for the PA and OA co-treatment group. To our surprise, two-cell
mouse embryos that were exposed to PA and OA co-treatment for 48 hours resulted in a
significantly lower percentage of LC3-II puncta per cell than the PA-alone group.
Additionally, PA and OA co-treatment resulted in similar levels of LC3-II puncta per cell
as the OA-alone group. This result suggests that the addition of OA in the co-culture
group relieved PA-treated embryos from the elevated level of autophagy seen at the 30
and 40 hours. I would propose that this outcome is again related to the differential uptake
kinetics that PA and OA display during mouse preimplantation development (Wang and
Tsujii 1999). Akoumi et al. (2017) reported that treatment of cardiomyocytes with PA
and OA preferentially stored fatty acids as DAG and TAG, respectively. The exponential
increase in OA uptake during the morula-blastocyst phase of preimplantation
development likely contributes to altered energy metabolism that negates PA individual
effects and restores appropriate embryonic homeostasis at the later stages of
preimplantation development. Aardema et al. (2011) reported significantly larger and
increased number of lipid droplets in bovine oocytes that were co-treated with PA and
OA in comparison to PA-alone treatment. Furthermore, a study of Chinese hamster ovary
cells suggested that the addition of OA in PA treatment re-directed lipid storage of PA
into triglycerides instead of generating reactive species like ceramides, thus preventing
cytotoxicity effects from PA accumulation (Listenberger et al. 2003). Mouse
preimplantation embryos also respond to PA and OA co-treatment similarly, where the
presence of OA in PA treatment alters lipid metabolic pathway and PA uptake into longterm storage as triglycerides (Yousif et al. 2020). It is likely that the redirection of PA
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into lipid droplets (as triglycerides) reduces PA metabolism to DAG and ceramide in the
cytosol that induces ER stress to thus lower autophagy required to maintain embryo
homeostasis. My study is the first report of this temporal aspect of OA rescuing effects in
mouse preimplantation embryos and the restoration of autophagic activity occurring
between 40 and 48 hours of NEFA treatment during mouse preimplantation development.
It is important to note that the OA-alone treatment for 48 hours beginning at the 2-cell
stage had no significant effect on the percentage of LC3-II puncta per cell compared to
controls, even though OA uptake should be significantly increased (Wang and Tsujii
1999; Yousif et al. 2020). Lee et al. (2019) reported no change in LC3-II protein
expression in hepatocytes after treatment of up to 200 µM OA. Similarly, in bovine
embryos, OA-alone treatment had no detrimental effects on preimplantation
development; OA treatment even significantly increased cleavage rates and blastocyst
development (Karaşahin and Arikan 2015). Although OA beneficial effects in mouse
embryos were not observed, it is agreed in the literature that OA treatment does not
impose negative effects on preimplantation development (Aardema et al. 2011; Karaşahin
and Arikan 2015; Lee et al. 2019). The LC3-II puncta observed in the
immunofluorescence images of the OA group likely represent basal levels of autophagy.
At the 48 hours time point, the relative percentage of LC3-II puncta per cell was
maintained at a high level in the PA treated group. The relatively high percentage of
LC3-II puncta per cell is suggestive of autophagosome accumulation in the PA-treated
embryos. If left in this condition it is likely that the accumulation of autophagosomes in
PA-treated embryos would result in a cytotoxic response in the embryos, that may
underlie the early developmental arrest observed in PA-treated embryos. Autophagosome
accumulation has a close relationship to cytotoxicity (Button et al. 2017). Button et al.
(2017) showed the buildup of autophagosomes in various cell lines with little lysosomal
activity results in a significant reduction in cell viability. In contrast, the reduction in
autophagosome formation to prevent autophagosome accumulation could alleviate
cellular toxicity (Button et al. 2017).
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Although quantification of LC3-II puncta is considered a gold-standard assay as a
measurement for autophagosome formation, there is a limitation to this method of
measurement. Runwal et al. (2019) reported that when HeLa cells were inhibited from
autophagy activation, LC3-I and p62 can aggregate and accumulate in the cytosol as
prominent LC3-positive structures. The study warns of potential misinterpretation of
LC3-I-p62 aggregates as LC3-II puncta and thus the confusion of autophagosome
structures when this method of measurement is employed (Runwal et al. 2019). We
cannot rule out the possibility that LC3-I-p62 aggregation may confound our findings in
the current study, but it highlights the need for future experiments to validate our
findings. Potentially through an alternate method of measuring autophagosomes
formation, for example, LC3-II protein expression analysis through western blot, may
confirm the effects of NEFA treatment on autophagosome accumulation in the present
study.

4.4 NEFA effects on autophagosome formation
The second primary objective was to characterize the effects of NEFAs on
autophagosome formation in preimplantation mouse embryos. In the first objective, it
was identified that 100 µM PA treatment results in a significant increase of relative
percentage of LC3-II puncta per cell after 30 hours of treatment. The observation that
more LC3-II puncta per cell was present in the PA group is reflective of autophagosome
accumulation at that treatment time point. Autophagy, however, is a dynamic process
consisting of autophagosome formation, maturation, and degradation. The accumulation
of autophagosomes is therefore a balance between the rate of autophagosome formation
and autophagosome degradation (Mizushima et al. 2010). Thus, it is important to
investigate autophagy at several different levels to characterize the underlying effects
brought upon by NEFA exposure on mouse preimplantation embryo autophagy. In the
present objective, the effects of NEFA treatments on autophagosome formation in
preimplantation mouse embryos were investigated by employing treatment with an
autophagy inhibitor chloroquine (CQ) that blocks autophagosome binding to lysosomes
(Mauthe et al. 2018).
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Mouse preimplantation embryos at the 2-cell stage were treated with NEFA treatments
for 40 hours with 75 µM CQ for the last two hours of treatment period. Although no
significant differences were found between each NEFA treatment groups with its
respective CQ-treated groups, treatment of PA with CQ resulted in a significantly greater
fluorescence of LC3-II puncta aggregate per cell than all other non-PA groups. Amongst
all groups, it is important to highlight that treatment of PA with CQ for 40 hours resulted
in a significantly greater fluorescence in LC3-II puncta aggregate per cell than CQ-only
group. After inhibiting autophagosome degradation for two hours using CQ, the
difference of LC3-II puncta fluorescence between PA+CQ group and CQ-only group is
likely indicative of a significant increase in autophagosome formation in the PA
treatment than that of controls. A previous study by Dhayal et al. (2019) reported that in
pancreatic β-cells, a significant increase in the number of autophagosome puncta was
observed after PA and Bafilomycin A1 (BafA1; autophagy inhibitor) treatment compared
to inhibitor-alone treatment. Similarly, Las et al. (2011) also reported increased
autophagosome formation in a PA treatment group with ammonium chloride and
leupeptin (NH4Cl/Leu) as autophagy inhibitors in INS-1 pancreatic β-cells. These studies
and mine show that PA treatment consistently results in the accumulation of
autophagosomes, by increasing autophagosome formation, in a variety of different cell
types.
Another crucial finding is that both OA+CQ and PAOA+CQ treatment for 40 hours
resulted in similar levels of fluorescence as the CQ-only group. This is suggestive of that
following blockade of autophagosome degradation for two hours with CQ, OA treatment
for 40 hours showed no independent effect on autophagosome formation from the control
group. Furthermore, the addition of OA in PA treatment also negated PA-induced
elevated levels of autophagosome formation. Very few other studies have investigated the
effects of OA treatment on autophagosome accumulation. OA treatment of MIN6
pancreatic β-cells for 24 and 48 hours significantly increased autophagosome formation
after inhibition of autophagosome degradation with CQ (Chu et al. 2019). It is interesting
that OA effects on autophagosome formation may differ depending on the cell-type.
Certainly, further experimentation is required to support my findings.
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However, these findings must be interpreted with caution as I am the first to employ CQ
treatment as an approach to investigate effects of autophagic inhibition on early
mammalian development. CQ treatment has of course been employed in many other
studies applied to various cell types, including primary neurons (Redmann et al. 2017)
and cancer cell lines (Mauthe et al. 2018; Leung et al. 2021), to name a few. However, no
consensus on dosage and treatment time was established between these studies as CQ
dosage can range from 25 µM to 100 µM while treatment time ranges from 5 to 24 hours.
The 2-hour CQ treatment time I employed arose from an assessment of the literature and
preliminary dose and treatment time experiments I conducted (see appendix A and B)
that identified 75 µM CQ treatment for 2 hours would resolve detectable differences in
LC3-II puncta if differences existed. However, the preliminary experiments were applied
to mouse blastocysts, which are at different stages than most of the embryos after 40
hours of NEFA treatment. Embryos of different preimplantation stages could exhibit
different rates of autophagosome formation. Further investigations are required to test
this concept.
It is also important to note that the current experiment quantified LC3-II “puncta
aggregate” per cell as fluorescence signals instead of puncta count (as previously reported
in objective 1). The reason behind this change in quantification method was because the
use of autophagy inhibitors (BafA1 and CQ) results in increased number and sizes of
LC3-II puncta aggregate, which likely represent autophagosome-autophagosome fusions
(Mauthe et al. 2018). The quantification of LC3-II based on fluorescent signals considers
the possible increase of sizes and number of LC3-II aggregates, which serves as a more
accurate assessment LC3-II after CQ treatment.

4.5 NEFA effects on autophagosome maturation and
degradation
My third objective assessed the effects of NEFAs on autophagosome maturation and
degradation in preimplantation mouse embryos. Autophagy consists of autophagosome
formation, maturation, and degradation so the net accumulation of autophagosomes is a
balance between the processes of autophagosome formation and autophagosome
degradation. It is important to investigate autophagy processes at several different levels
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to fully characterize the underlying effects brought upon by NEFA exposure on
preimplantation embryos.
Two-cell mouse embryos were treated with NEFA treatments for 40 hours then immunolabelled to identify for autophagosome-lysosome fusion based on autophagosomelysosome co-localization. The co-localization of LC3-II-lysotracker puncta were
analyzed to determine autophagosome maturation. My results indicate a significantly
greater average number of LC3-II-lysotracker co-localized puncta per cell in the OA
group than in the PA group, which suggests that treatment with 250 µM OA results in
greater autophagosome maturation than treatment with 100 µM PA. I also observed that
250 µM OA treatment resulted in a significantly higher proportion of LC3-II-lysosome
co-localized puncta per cell (relative to the number of LC3-II puncta per cell) than 100
µM PA treatment. Altogether, my results strongly suggest that a higher number and
proportion of autolysosomes was observed in the OA treatment group compared to the
PA group. Induction of autophagosome maturation by OA treatment was reported in
tongue squamous cell carcinoma cell lines (Jiang et al. 2017); however, this was not
observed in a study employing HepG2 cells (Lee et al. 2019). I would suggest that, as
mentioned previously, it is likely that OA effects differ among cell types.
Interestingly, I did not detect a change in autophagosome maturation in mouse embryos
after treatment of PA compared to control. Similarly, exposure of hypothalamic neuronal
cells to PA treatment also showed no difference in autolysosome number from control
(Hernández-Cáceres et al. 2020). Studies of pancreatic β-cells, however, have reported
significant increases in autophagosome maturation, reflected by a higher percentage of
autophagosome-lysosome fusion, after treatment with PA (Dhayal et al. 2019; Choi et al.
2009). It is important to note that limited studies have investigated the effects of PA on
autophagosome maturation in embryos as well as the effects of PA and OA in
combination on autophagosome maturation.
Next, I investigated the effects of NEFA treatment on autophagosome degradation in
mouse preimplantation embryos. Fluorescence intensity of a lysosomal dye, LysoTracker
Red, as to reflect lysosomal activity, were analyzed in NEFA-treated mouse embryos
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with references to the protocol by Albrecht et al. (2020). No significant differences in
lysosomal activity were found between control, OA, and PA and OA co-treatment
groups. Though, compared to the other treatment groups, treatment of 100 µM PA
resulted in significantly less LysoTracker fluorescence, which could suggest a
significantly lower level of lysosomal activity. In support of the previous findings, the
accumulation of autophagosomes observed after PA treatment could be due to a reduction
of lysosomal activity and thus lower level of autophagosome degradation in PA-treated
mouse preimplantation embryos. The disruption of autophagy mechanisms by lowering
lysosomal activity could contribute to developmental incompetency in PA-treated
embryos. Chu et al. (2019) previously reported that, in contrast to our findings, both PA
and OA treatments do not affect lysosome size and numbers in MIN6 pancreatic β-cells;
however, both PA and OA treatments increased lysosomal acidity, which the authors
considered was an improvement in lysosomal activity. Regardless, lysosomal activity is
an important aspect of autophagosome degradation in preimplantation embryo
development that requires further experimentation.
The role of the lysosome in autophagy shines light on the potential mechanistic changes
by PA treatment. A study by Hernández-Cáceres et al. (2020) reported that PA disrupts
autophagic flux by decreasing autophagosome-lysosome fusion in hypothalamic neuronal
cells. Though, PA does not lower lysosomal activity; instead, it lowers the motility of
lysosomal compartments by accumulating of Rab7 GTPase (Hernández-Cáceres et al.
2020). Rab7 GTPase is located on lysosomes that attaches to a motor unit to facilitate the
transport of autophagosome towards a lysosome (Jordens et al. 2001). Additionally, it
facilitates autophagosome-lysosome fusion by recruiting tethering proteins like SNARE
proteins (Ganley 2013). However, the activation of Rab7 GTPase require hydrolysis of
the attached GTP to GDP to utilize the energy for its function. The accumulation of Rab7
GTPase after treatment of PA results in reducing autophagosome movement towards
lysosomes, thus lowering autophagosome-lysosome fusion and disrupting autophagy in
the hypothalamic neuronal cells (Hernández-Cáceres et al. 2020). It is unknown whether
Rab7 GTPase is affected by PA treatment in preimplantation mouse embryos, but such a
mechanism would be interesting and important to investigate in future experiments. It is
postulated that PA may similarly disrupt the hydrolysis of Rab7 GTPase in the mouse
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preimplantation embryos, thereby preventing autophagosome-lysosome fusion necessary
for autophagosome degradation and thus resulting in impairments in development to the
blastocyst stage.
Although OA resulted in no effects in development or autophagy, OA treatment has been
previously described to promote the accumulation of lipid droplets during mouse
preimplantation development (Yousif et al. 2020). Nakajima et al. (2019) reported an
induction of lipid droplet accumulation after OA treatment in astrocytes that contributes
to offsetting PA-induced lipotoxicity. A similar mechanism is likely in place in
preimplantation mouse embryos as well, as the addition of OA to PA treatment
successfully negated PA-induced reduction in lysosomal activity. With the high levels of
lysosomal activity observed in the OA group in my study, it is possible that lysosomes
take part in the break down of the accumulated lipid droplets via autophagy, a mechanism
specifically described as lipophagy (Schulze et al. 2020), to produce energy to counteract
PA effects. Further investigations, of lipophagy, would be beneficial to generating a full
understanding the OA treatment effects in alleviating PA-effects.
My outcome interpretations must be made with caution as the analysis of LysoTracker
fluorescence signal of NEFA-treated embryos as a measurement of lysosomal activity is
novel. The use of LysoTracker Red is primarily employed for live cell imaging although
it can be readily applied to fixed cells (Raben et al. 2009). My preliminary investigations
with this method, defined appropriate LysoTracker dye concentration and treatment times
for application to fixed preimplantation stage embryos. I observed that LysoTracker
fluorescence signal rapidly declines in mouse preimplantation embryos after fixation and
time progression. Thus, I modified the current standardized method to employ a higher
concentration of LysoTracker (500 µM vs. 50 µM of LysoTracker for 30 mins). This
novel approach did not have any observable morphological effects but there is a
possibility of some lysosome alkalinization happening caused by the slightly basic nature
of LysoTracker (pH=9). Alternative methods to immunolabel lysosomal proteins with
LAMP1 and LAMP2, for example, could be included in future experiments to confirm
the current findings.
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Overall, my results provide important insight on the consequences of PA and OA
treatment effects on autophagosome-lysosome fusion during mouse preimplantation
development for the first time.

4.6 Conclusion and Significance
This thesis presents new outcomes from experiments that investigated the effects of PA
and OA treatment on preimplantation development, autophagy, autophagosome
formation, and autophagosome degradation in mouse preimplantation embryos.
PA treatment beginning at the 2-cell stage impaired blastocyst development by arresting
mouse embryos at the 4- 8-cell stage. The significant accumulation of autophagosomes in
the later stages of embryo development observed was likely a result of elevated
autophagosome formation as well as lowered levels of autophagosome maturation and
degradation modulated by adjustments in lysosomal activity. OA treatment beginning at
the 2-cell stage had no significant effects on preimplantation development,
autophagosome formation, or autophagosome degradation.
The effects of PA and OA co-treatment of mouse preimplantation embryos beginning at
the 2-cell stage was time-dependent. A delay in development was identified at the early
cleavage stages but affected embryos restored blastocyst development frequency to
control levels. A correlation was observed between development and autophagy as the
restoration of blastocyst formation coincided with the restoration of control autophagy
levels at the later stages of preimplantation embryo development. Interestingly, although
high levels of autophagosome accumulation was observed after 40 hours of PA and OA
co-treatment, levels of autophagosome formation, maturation, and degradation were not
significantly different than control at that time point. Perhaps autophagosome
accumulation observed after 40 hours of co-treatment was a result of aberrant early
cleavage stage embryo buildup overseen by rapid PA effects that were alleviated by OA
rescue and adjustment of the autophagic pathway back to control levels at 48 hrs of cotreatment. The 40-hour time point could likely be within the period of the “catch-up
growth” mentioned in the first experiment, thus further experimentation is required to
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fully understand NEFA effects on autophagy at a shorter time interval between 30- and
48-hour treatment of 2-cell embryos, potentially of 6-hour time intervals.
The general objective of my thesis was to understand the underlying autophagic
mechanisms impacted by NEFA treatments during early mouse embryo development in
vitro. My findings are summarized in Figure 22.
Overall, this thesis reports the effects of NEFA treatments on embryo development and
autophagic

mechanisms

throughout

preimplantation

development.

The

results

demonstrated a correlation between embryo development and autophagy, and that
autophagic mechanisms are likely altered by NEFA treatments. Future experiments shall
include embryonic stem cells as an alternate model for preimplantation embryos when
investigating the effects of NEFAs on early mammalian autophagy, as ES cells nicely
replicate ICM cells of blastocyst stage embryos. Some preliminary experiments of NEFA
effects on autophagy of mESC were completed (Appendix D). These findings will
advance our understanding of the effects of NEFAs on preimplantation embryo
autophagy. They will also guide future investigations that may eventually employ
autophagic modulation, perhaps by OA treatment, as a therapeutic option to enhance
developmental success. It is our goal to assist patients who are seeking ARTs for their
fertility needs, especially of those who are obese.
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Figure 22. Summary Figure: Effects of PA and OA on autophagy in mouse
preimplantation embryos.
Autophagy begins when a phagosome is initiated to form an autophagosome. A
phagosome recruits autophagy-related proteins to direct degradation contents into the
phagosome as it elongates and seal off to become an autophagosome. After
autophagosome formation is completed, autophagosome is transported to a lysosome for
autophagosome maturation. Fusion of autophagosome and lysosome creates an
autolysosome. Acidic contents of the lysosomes degrade the autophagosome, then
releasing the degraded contents into the cytosol for reuse in other cellular functions. PA
treatment of mouse preimplantation embryos was observed to increase autophagosome
accumulation by elevating autophagosome formation, reducing autophagosome
maturation, and reducing autophagosome degradation by disruption of lysosomal activity.
In contrast, OA-alone treatment of mouse preimplantation embryos has no effects on
autophagy. The addition of OA in PA treatment was observed to inhibit PA-induced
effects on preimplantation embryo autophagy, but only after 40 hours of co-treatment.
Created with BioRender.com.
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Appendix A: Western blot assay for preimplantation embryos
Western blot is an effective assay for the quantification of protein levels in cell and tissue
samples. However, there are very few studies that utilize western blot for the
quantification of protein expression in preimplantation embryos due to the low total
protein levels and thus high number of embryos required to apply this type of analysis.
However, as an important alternate assay for the analysis of autophagic markers like
LC3-I and LC3-II, it is essential to include western blot data as part of the analysis. I
adapted the mESCs western blot protocol for application to detecting these proteins in
preimplantation mouse embryos. With the goal of measuring autophagic markers in
preimplantation embryos, I explored the number of mouse blastocysts required per lane
that is sufficient to measure protein abundance of LC3-I and LC3-II. Mouse embryos at
the 2-cell stage were cultured in KSOMaa medium for 48 hours and collected at the
blastocyst stage. After which, a western blot consisting of different numbers of
blastocysts per lane was conducted for the detection of LC3-I and LC3-II. An mESCs
pool sample was included as a positive control. Thus, it was established that at least 40
blastocyst stage embryos are required for the detection of LC3-I and LC3-II in mouse
preimplantation embryos via western blot. Representative image of the western blot is
shown in supplementary figure 1.
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Supplementary figure 1. Representative image of a western blot using mouse
preimplantation blastocyst embryos of various number of embryos per lane for the
detection of LC3-I (16 kDa), LC3-II (14 kDa), and β-actin (45 kDa; loading control).
Mouse embryos at the 2-cell stage were cultured in KSOMaa medium for 48 hours and
collected at the blastocyst stage prior to western blot analysis.
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Appendix B: Chloroquine assay to measure autophagic flux
Chloroquine (CQ) is an autophagy inhibitor that alters the acidity of lysosomal
compartments thus preventing the fusion of autophagosomes to lysosomes for
degradation (Mauthe et al. 2018). Very few studies have used CQ as an autophagy
inhibitor in mouse preimplantation embryos; and for the studies that used CQ in other cell
types, no common consensus were established for treatment concentration and time
periods. Thus, with consideration of published studies that used CQ in their respective
cell types, I investigated the dosage response of 2-hour treatment of CQ on mouse
preimplantation embryos. Mouse embryos at the 2-cell stage were cultured in KSOMaa
medium for 48 hours and treated with 0, 20, 50, 75, or 100 µM of CQ at the last two
hours of treatment period. Then, embryos were collected at the end of the treatment
period for the analysis of LC3-II expression through western blot and for the analysis of
LC3-II puncta count through immunofluorescence.
After two hours of CQ treatment post-culture incubation, morphological changes in the
mouse preimplantation embryos were visually assessed under a phase contrast
microscope. Exposure to CQ up to 100 µM for two hours did not result in visible
morphological changes compared to non-treated control. Supplementary figure 2
displays the representative images of the mouse embryos post-CQ exposure.
Mouse embryos collected after morphological evaluation were subjected to protein
extraction for western blot analysis of LC3-I and LC3-II or immunofluorescence staining
for LC3-II puncta. It was revealed that at least 50 µM of CQ for two hours is required for
detectable differences in LC3-II expression via western blot analysis (Supplementary
figure 3, P < 0.05, Tukey’s multiple comparisons test). On the other hand, it was found
that at least 75 µM of CQ for two hours is required for detectable differences in LC3-II
puncta count via immunofluorescence staining technique (Supplementary figure 4A, P
< 0.05, Tukey’s multiple comparisons test). Representative images of embryos after CQ
exposure for two hours are shown in supplementary figure 4B.
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Thus, it was established that exposure of CQ at 75 µM for two hours to mouse
preimplantation embryos would allow for detectable differences in autophagic marker
expression through western blot and immunofluorescence analysis.
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Supplementary figure 2. Representative images of mouse preimplantation embryos
treated with various concentrations of chloroquine at the last two hours of treatment
period. Scale bar = 75 µm.
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Supplementary figure 3. Protein expression of LC3-II of blastocyst embryos under
various concentrations of chloroquine treatment for 2 hours, analyzed by Western Blot (+
SEM). Normalized to β-actin; 30 – 40 blastocysts per lane. N=3, one-way ANOVA with
Tukey’s HSD post-hoc test. Significant differences are indicated by *p < 0.05; ** p <
0.005. Representative images of western blot of LC3-I (16 kDa), LC3-II (14 kDa), and βactin (45 kDa; loading control).
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Supplementary figure 4. Number of LC3-II protein aggregates observed in blastocysts
treated with various concentrations of chloroquine treatment for 2 hours, analyzed by
immunofluorescence (+ SEM). N=3, one-way ANOVA with Tukey’s HSD post-hoc test.
Significant differences are indicated by *p < 0.05. Representative fluorescent images of
mouse embryos after CQ exposure for 2 hours. Scale bar = 100 µm.
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Appendix C: Chloroquine effects on preimplantation
development
I investigated the effects of 75 µM of CQ on preimplantation embryo development. I
exposed 2-cell mouse embryos to 75 µM of CQ for 14 and 48 hours. Developmental
stage progression was assessed, and the embryos were analyzed for LC3-II puncta count.
After 14 hours of CQ exposure, there was a significant reduction in progression to the 4cell stage compared to control (Supplementary figure 5A, P < 0.001, Sidak’s multiple
comparisons test). Correspondingly, 14 hours of CQ exposure resulted in a significant
increase in embryos at the 2-cell stage compared to control (Supplementary figure 5A,
P < 0.0001, Sidak’s multiple comparisons test). Representative images of 2-cell mouse
embryos to placed into KSOMaa medium alone (control) or under treatment with 75 µM
of CQ for 14 hours are shown in supplementary figure 5C.
After 48 hours of CQ exposure, there was no progression of 2-cell embryos to the 8-cell,
morula, and blastocyst stages; though only blastocyst development compared to control
was considered statistically significant (Supplementary figure 5C, P < 0.0001, Sidak’s
multiple comparisons test). Correspondingly, 48 hours of CQ exposure resulted in
significantly more embryos arresting at the 2-cell stage and greater development of
embryos to the 4-cell stage compared to control (Supplementary figure 5A, P < 0.05,
Sidak’s multiple comparisons test). Representative images of 2-cell mouse embryos
placed into to KSOMaa medium alone (control) or with 75 µM of CQ treatment for 48
hours are shown in supplementary figure 5C.
Analysis of LC3-II puncta through immunofluorescence revealed significantly greater
LC3-II puncta count per cell in CQ group compared to control group, at both 14 and 48
hours of exposure (Supplementary figure 6A and 6C, P < 0.05, two-tailed unpaired ttest). Representative images of exposing 2-cell mouse embryos to KSOMaa medium
alone (control) or under 75 µM CQ treatment for 14 and 48 hours are shown in
supplementary figure 6B and 6D, respectively.
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Supplementary figure 5. Developmental progression (+ SEM) of 2-cell mouse embryos
in 75 µM of CQ or KSOMaa medium alone (control) for 14 (A) and 48 hours (B).
Percent development to each embryo stage was analyzed. N=3, two-way ANOVA with
Sidak’s multiple comparisons test. Significant differences are indicated by *p < 0.05,
***p < 0.001, and ****p < 0.0001. Representative images of 2-cell mouse embryos in
KSOMaa medium alone (control) or in 75 µM of CQ for 14 and 48 hours (C).
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Supplementary figure 6. Relative LC3-II puncta aggregate per cell (+ SEM) of 2-cell
mouse embryos in 75 µM of CQ or KSOMaa medium alone (control) for 14 (A) and 48
hours (C). N=3, two-tailed unpaired t-test. Significant differences are indicated by *p <
0.05. Representative images of 2-cell mouse embryos in KSOMaa medium alone
(control) or 75 µM of CQ for 14 (B) and 48 hours (D).
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Appendix D: Effects of PA and OA on mESC autophagy
Mouse embryonic stem cells (mESC) are derived from inner cell mass of a mouse
blastocyst. mESCs represent an excellent alternate model for the investigation of NEFA
treatment effects to early mammalian developmental autophagy, and preimplantation
stages. R1 wild type mESCs were cultured in KSOMaa (BSA control), and KSOMaa plus
100 µM PA and 250 µM OA, individually and in combination, for 48 hours. Medium
control consisting of only mESC growth media was also included in the experimental
design.
Supplementary figure 7 summarizes the findings from this experiment. Densitometric
analysis of western blot of LC3-I was not significantly different across treatment groups
(Supplementary figure 7A, P > 0.99, Tukey’s multiple comparisons test) except for the
mESC medium control (Supplementary figure 7A, P < 0.05, Tukey’s multiple
comparisons test). No differences in LC3-II protein levels were detected between all
treatment groups (Supplementary figure 7B, P > 0.05, Tukey’s multiple comparisons
test). The ratio of LC3-II to LC3-I protein levels, however, were significantly higher in
the PA-alone and OA-alone groups compared to mESC medium control (Supplementary
figure 7C, P < 0.05, Tukey’s multiple comparisons test). PA-alone and OA-alone groups
were not significantly different from each other. Supplementary figure 7 includes
representative images of western blot of LC3-I and LC3-II. The western blot also
confirms the specificity of the LC3 antibody used in this thesis.
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Supplementary figure 7. Protein expression of LC3-I (A), LC3-II (B), and the ratio of
LC3-II:LC3-I (C) of mESCs in 100 µM PA, 250 µM OA, 100 µM PA and 250 µM OA,
KSOMaa media (BSA control), or mESC growth medium (media control) for 48 hours (+
SEM). N=3, one-way ANOVA with Tukey’s HSD post-hoc test. *p < 0.05.
Representative images of western blot of LC3-I (14 kDa) and LC3-II (16 kDa) included
in A-C. Ponceau S as loading control (D).
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